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ABSTRACT 
∆9-Tetrahydrocannabinol (THC) is the primary active ingredient of the plant Cannabis sativa 
(marijuana), responsible for the majority of the pharmacological effects. The most promising 
clinical applications of THC approved by the Food and Drug Administration (FDA) are for the 
control of nausea and vomiting associated with chemotherapy and for appetite stimulation of 
AIDS patients suffering from anorexia and wasting syndrome. The only dosage form currently 
approved by FDA is an oral, soft gelatin capsule (e.g. Marinol
®
). In addition, orally administered 
THC from Marinol
®
 has shown slow and variable absorption due to low oral solubility and first 
pass metabolism. Our strategy towards developing THC transmucosal formulations involved 
development of hydrophilic prodrugs of THC and solubilization and stabilization of prodrugs in 
oral formulations. In the present study, the hemisuccinate ester of THC (THC-HS) has been 
investigated for its potential to form inclusion complexes with modified synthetic beta-
cyclodextrins (CDs). The formation of 1:1 inclusion complexes of THC-HS with random 
methylated beta-cyclodextrin (RAMEB) and 2-hydroxypropyl beta-cyclodextrin (HPBCD) was 
demonstrated by an AL type curve with the slopes less than unity by the phase solubility method. 
We evaluated the effect of RAMEB and HPBCD on chemical and enzymatic stability and in 
vitro permeation across excised buccal mucosa of THC-HS. There was a significant reduction in 
chemical hydrolysis of complexed prodrug as compared to free prodrug. RAMEB afforded better 
stability profile and lower degradation rate constants as compared to HPBCD at all the pHs 
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tested and in enzymatic conditions too. In vitro permeation experiments demonstrated almost 63-
fold increase in the permeability of THC-HS across excised buccal mucosa, in the presence of 
RAMEB as compared to the surfactants. Lyophilized solid dispersions of THC-HS with RAMEB 
and HPBCD were evaluated for their stability and drug release characteristics. RAMEB proved 
superior to HPBCD in enhancing the stability of THC-HS in solid dispersions as well as the rate 
of release of the prodrug from the solid dispersions. Finally design of experiments approach was 
implemented by proposing a 2
3
 factorial design to identify critical formulation variables required 
in the development of transmucosal polymeric films of THC-HS with enhanced solubility and 
stability. 
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CHAPTER 1 
INTRODUCTION 
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1.1. ∆9-Tetrahydrocannabinol 
The use of herbal marijuana in medicinal applications like multiple sclerosis and 
alzheimer‘s disease in now being widely discussed in both the medical and lay literature. Ballot 
initiatives in California and Arizona have made medical marijuana legal under certain 
circumstances. Most recently, the California Proposition 19 which sought to legalize various 
marijuana-related activities in California (although not as a matter of federal law), allowing local 
governments to regulate these activities, permitting local governments to impose and collect 
marijuana-related fees and taxes, and authorizing various criminal and civil penalties was 
defeated.  
Marijuana has been widely used for hundreds of years as an addiction aid or herbal 
remedy. Pure ∆9-tetrahydrocannabinol (THC) is the one of the major active constituent out of 66 
constituents of cannabis sativa. The crude marijuana, an undefined herb containing 
approximately 480 substances has not been approved by the US Food and Drug Administration 
for use as a medicine.
1,2
  
 THC is the main source of the pharmacologic effects of cannabis and most of its effects 
are mediated through agonistic action cannabinoid (CB) receptors. To date, two subtypes of 
these receptors have been identified, the CB1 receptor (cloned in 1990) and CB2 receptor 
(cloned in 1993), both coupled through inhibiting G proteins (Gi proteins), negatively to 
adenylate cyclase and positively to mitogen- activated protein kinase. Activation of Gi proteins 
causes inhibition of adenylate cyclase, thus inhibiting the conversion of AMP to cyclic AMP. A 
total of 66 phytocannabinoids have been identified, most of them belonging to several subclasses 
or types: the cannabigerol CBG), cannabichromene (CBC), cannabidiol (CBD), ∆9-THC, ∆8-
THC, cannabicyclol (CBL), cannabielsoin (CBE), cannabinol (CBN), cannabinodiol(CBDL) and 
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cannabitriol (CBTL) types. The cannabinoid acids of Δ9-THC, CBD, CBC and CBG are the 
quantitatively most important cannabinoids present in the plant. The cannabinoid acids of THC 
are devoid of psychotropic effects and have to be decarboxylated to the phenols to produce 
marijuana-like effects, e.g. by smoking the dried plant matter. 
3
 
 
Figure 1-1 Structure of ∆9-THC 
Natural Δ9-THC has two chiral centres at C-6a and C-10a in the trans configuration. 
Usually the acronym THC is applied to this naturally occurring (–)-trans-isomer of Δ9-THC, and 
will be used in this text as well. The generic name for Δ9-transtetrahydrocannabinol is 
dronabinol. Marinol™ (Unimed Pharmaceuticals, Inc.) contains synthetic dronabinol, dissolved 
in sesame oil, as capsules of 2.5, 5 and 10mg of dronabinol.  
1.2. Physicochemical Properties and Degradation of THC 
THC and many of its metabolites are highly lipophilic and essentially water-insoluble.
4
 
Calculations of the n-octanol/water partition coefficient (Kow) of THC at neutral pH vary 
between 6000 using shake-flask methodology.
5
 The wide range for aqueous solubility and Kow, 
can be attributed to the difficulty of uniformly dissolving this essentially water-insoluble 
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substance and accurately measuring small amounts of it. The spectrophotometric pKa is 10.6.
4
 
THC is thermolabile and photolabile.
6,7
 Storage leads to a cumulative decrease in THC content 
through oxidation of THC to CBN.
8,9
 THC rapidly degrades in acid solutions. The kinetics seem 
to be first order and specifically hydrogen ion-catalysed so that significant degradation is 
assumed to occur in the normal stomach with a half-life of 1 hour at pH 1.
4
 Decarboxylation of 
the THC acids to the corresponding phenols occurs readily over time, upon heating or under 
alkaline conditions.
8,9
 Heating for 5 minutes at a temperature of 200–210°C has been reported to 
be optimal for this purpose, but a few seconds in burning cannabis cigarettes are equally 
sufficient. Slow decarboxylation of THC acid occurs at room temperature. 
1.3. Pharmacokinetics of Δ9-Tetrahydrocannabinol 
Cannabis products are commonly either inhaled by smoking a cannabis cigarette, taken 
orally as dronabinol capsules or in baked foods or liquids. Various other routes of administration 
and delivery forms have been tested for therapeutic purposes. The rectal route with suppositories 
has been applied in some patients,
10
 and dermal
11
 
and sublingual
12
  administration are under investigation. Other methods include eye drops 
to decrease intraocular pressure,
13
 as well as aerosols and inhalation with vaporisers to avoid the 
harm associated with smoking.
14,15
 The kinetics of cannabinoids are much the same for females 
and males,
16
 as well as for frequent and infrequent users.
17,18
 
1.4. Therapeutic indications of THC 
Several pharmacological effects of THC may well be clinically useful. One of the most 
prominent therapeutic uses of THC is its anti-emetic effect in cancer chemotherapy. Another is 
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the ability to lower increased intraocular pressure, as occurs in glaucoma. Another potential use 
of THC is as a bronchodilator in the treatment of patients with bronchitis and asthma. There are a 
variety of actions on the central nervous system associated with THC administration for 
therapeutic purposes. A syndrome of feelings described as a ―high‖ often occurs. This euphoria 
includes such effects as elation, heightened awareness, giddiness and some distortions of 
activities and interactions with other people.  Some researchers have found that the production of 
a ―high‖ correlates well with its anti-emetic activity. Unpleasant effects on the central nervous 
system have also been reported, including visual hallucinations and severe, continuous 
depersonalization.  
By far, most research on THC has involved the use of oral THC (dronabinol) for the 
treatment of nausea and vomiting in cancer chemotherapy as well as appetite loss in AIDS 
wasting syndrome.  
1.5. Cannabinoid therapy: Design of formulation systems for various 
routes of administration 
There have been number of attempts to develop formulation systems for administration 
via oral, sublingual transdermal routes for the USFDA approved indication inc ancer 
chemotherapy. 
1.5.1. Oral administration of cannabinoids 
Synthetic THC is known as dronabinol. It is available as a prescription drug (under 
Marinol
®
 in several countries including the United States and Germany. In the United States, 
Marinol is a Schedule III drug, available by prescription, considered to be non-narcotic and to 
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have a low risk of physical or mental dependence. Marinol has been approved by the U.S. Food 
and Drug Administration (FDA) in the treatment of anorexia in AIDS patients, as well as for 
refractory nausea and vomiting of patients undergoing chemotherapy. However, the reduced 
bioavailability of orally administered THC, due to low absorption and high first pass 
metabolism, prompts the development of more reliable administration forms such as THC 
solutions for inhalation, sublingual or transdermal films.  
1.5.2. Transdermal administration of cannabinoids 
The skin permeation behavior of THC, cannabidiol and cannabinol has been investigated 
in several experimental studies. The transdermal administration increases the duration of action 
compared with all the other routes of application. This is advantageous in users requiring control 
of long-term pain and other applications with continuous effects. Since cannabinoids are highly 
lipophilic molecules, they accumulate within the upper skin layer (Stratum corneum) and 
permeate slowly to lower strata. Hence their effective subcutaneous administration requires 
permeation enhancement. In a study by Touitou et al,
19
 which used the more stable ∆8 THC 
isomer, the permeability coefficient of THC was significantly enhanced from the formulations 
containing oleic acid in propylene glycol/water/ethanol. Significant THC concentrations were 
found in the blood of hairless rats treated with formulations containing THC 26.5 mg/g. In 
several in vitro experiments carried out by Stinchcomb et al,
11
 mean flux rates for ∆8-THC, 
cannabidiol and cannabinol through samples ranged from 0.73 to 4.67 nmol/cm
2
/h. They used 
cannabinoid solutions in propylene glycol/water/ethanol mixtures of various concentrations. An 
ethanol concentration of 30-33% gave the highest flux rates. Based on a THC clearance of 14 
L/h and an average plasma level of 10 ng/ml, a required therapeutic delivery rate of THC of 
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about 9 nmol/cm
2
/h can be estimated which is somewhat closer to that achieved in the studies by 
Stinchcomb and colleagues.  
A transdermal delivery system for cannabidiol involving the use of ethosomal carriers has 
also been designed. Ethosomes are malleable vesicles tailored for enhanced delivery of active 
agents. They are composed of phospholipids, ethanol, and water and encapsulate and deliver, 
through the skin, highly lipophilic molecules such as cannabinoids, testosterone, and minoxidil, 
as well such as propranolol and trihexyphenidil. In vivo administration of ethosomal cannabidiol 
to nude mice produced significant amounts of drug in the skin and in the underlying muscle.
20
 
Valiveti et al developed a transdermal therapeutic system to deliver ∆8-THC. The plasma 
concentration of ∆8-THC reached a mean steady-state level of 4.4 ng/ml within 1.4 h and was 
maintained for at least 48 h.
21
 
1.5.3. Sublingual administration of cannabinoids 
Sativex® is a cannabis-based pharmaceutical product containing ∆9-tetrahydrocannabinol 
(THC) and cannabidiol (CBD) in a 1:1 ratio, delivered in an oromucosal (mouth) spray.  Each 
spray of Sativex delivers a fixed dose of 2.7mg THC and 2.5mg CBD. It has been approved as 
adjunctive treatment for neuropathic pain in patients with multiple sclerosis (MS) in UK and 
Canada. It is being investigated for the management of other MS symptoms, such as spasticity. 
THC:CBD spray is regulated as a narcotic. Five randomized controlled trials (RCTs) compared 
the benefits and harms of THC:CBD spray with placebo. A total of 368 patients with various 
neurological conditions (including MS) were recruited. In some trials, THC:CBD spray 
significantly reduced neuropathic pain, spasticity, muscle spasms and sleep disturbances. The 
most common adverse events (AEs) reported in trials were dizziness, sleepiness, fatigue, feeling 
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of intoxication and a bad taste. Long-term safety and the potential for dependence, abuse, misuse 
and diversion are unknown.
12
 
1.5.4. Buccal administration of cannabinoids 
Despite the promising clinical potential of THC, an effective dosage form for delivery of 
THC has not been developed to date. This is mainly attributed to its pharmacokinetic limitations 
and poor physicochemical properties. THC is a poorly water-soluble, amorphous substance 
which is sticky, resin-like and highly viscous making it difficult to handle and process. 
Furthermore, THC is an unstable drug. In acidic environment and in presence of heat, it 
undergoes hydrolysis to yield cannabidiol and in presence of air it undergoes oxidation 
producing cannabinol as the degradation product. Degradation due to visible light is also 
reported.
8
 The prodrug approach has been the most successful strategy in improving the 
pharmaceutical, pharmacokinetic, and pharmacodynamic properties of drugs. Prodrugs are 
pharmacologically inactive derivatives of active drugs designed to maximize the amount of 
active drug that reaches its site of action, through manipulation of the physicochemical, 
biopharmaceutical or pharmacokinetic properties of the drug.
22-27
 
Prodrugs are converted into the active drug within the body through enzymatic or non-
enzymatic reactions. To overcome the pharmacokinetic limitations and improve the 
physicochemical properties of the parent drug, several prodrugs of THC have been developed 
and investigated. These include THC-hemisuccinate (THC-HS), THC-hemiglutarate (THC-
HG).
28
 Several researchers have studied the stability and bioavailability of THC-HS in various 
dosage forms. Elsohly et al have investigated the possibility of delivering THC-HS via the rectal 
route of administration. Studies carried out using THC-HS in a lipophilic base in dogs exhibited 
approximately 64 % bioavailability. 
29
Munjal et al have investigated the possibility of delivering 
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the prodrug via oral transmucosal route. The authors studied the stability of THC-HS when 
incorporated into poly (ethylene oxide) matrices via hot-melt casting methods.
30,31
 THC-HG is 
another prodrug of THC which was developed to overcome the solubility and stability issues 
associated with THC. The formulation development of THC-HG transmucosal films has been 
studied by Thumma et al where the main focus was the stabilization of THC-HG in hot-melt 
polymeric matrices.
32,33
  
1.6. Transmucosal Delivery of cannabinoids 
Due to the significant limitations associated with traditional routes of administration, 
several non-parenteral routes such as nasal, ocular and transdermal have also been explored for 
the systemic delivery of THC. While each of these routes has its own disadvantages, the oral 
transmucosal route has several advantages. The intra-oral mucosal route has easy accessibility, 
an expanse of smooth muscle and relatively immobile mucosa and hence is suitable for 
administration of retentive dosage forms. Drugs administered by this route bypass the first pass 
metabolism and gain direct access to the systemic circulation through the internal jugular vein 
leading to a high bioavailability. Oral mucosal delivery is non-invasive and less intimidating for 
patients as compared to other routes of administration (e.g. intravenous and intra muscular). The 
oral cavity serves as a useful site for delivery for patients suffering with nausea or vomiting, or in 
a state of unconsciousness, with an upper gastrointestinal tract disease or surgery which affects 
oral absorption, or those who have difficulty swallowing the peroral medications. Other 
advantages include low enzymatic activity, suitability for drugs that are susceptible to acid 
hydrolysis in the stomach, painless administration, easy drug withdrawal in case of toxicity, 
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facility to include permeation enhancer/enzyme inhibitor or pH modifiers in the formulation and 
versatility in designing as multidirectional or unidirectional release 
systems for local or systemic actions. The small surface area, salivary wash out of the 
dissolved drug and barrier property of buccal mucosa stand as the major limitations in the 
development of buccal adhesive drug delivery systems. However, these limitations can be 
overcome by tailoring the formulation to include permeation enhancers and bioadhesive 
polymers. 
1.7. Problems associated with the prodrug approach 
The other problems associated with transmucosal oral delivery of THC prodrugs are: a) 
high instability to heat and hydrolysis and prone to oxidation, b) the poor solubility of the 
prodrug (better than the parent drug) making its absorption, dissolution rate- limited, and c) since 
the prodrug is sticky and resinous in nature, handling issues are a major concern in formulation 
of the drug. Hence, suitable methods need to be employed to make it free-flowing. At this stage, 
a solubilization approach might be needed to enhance the solubility of THC-HS and maintain a 
higher concentration in the gastrointestinal tract (GIT) in order to enhance absorption.  Earlier, 
attempts have been made by Repka et al to enhance the solubility and stability of THC-HS and 
THC-HG using different polymers, solubilizers, anti-oxidants and pH modifiers. These 
solubilization methods were only moderately successful in increasing the solubility of the 
prodrugs warranting a better solubilization strategy. One of the most commonly explored 
technologies to enhance the solubility and, in turn, the absorption of water-insoluble drug 
molecules from the GIT is the use of cyclodextrin complexation of drugs. 
34
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1.8. Cyclodextrins as solubilizing agents for enhanced oral bioavailability  
Cyclodextrins have been used extensively in pharmaceutical research and development, 
and there are currently over 30 marketed cyclodextrin-containing pharmaceutical products 
worldwide.
34
 Cyclodextrins possess a unique ability to complex with drugs enabling them to 
increase solubility, reduce bitterness, enhance stability, and decrease tissue irritation upon 
dosing. One of the most common applications of cyclodextrins cited in the pharmaceutical 
literature is the enhancement of solubility and in turn increasing the bioavailability of the drug. 
Cyclodextrins are cyclic oligosaccharides composed of 6-8 dextrose units (α-, β-, γ-
cyclodextrins, respectively) joined through 1-4 bonds.
35
 Because the interior of these molecules 
are relatively hydrophobic and the exterior relatively hydrophilic, they tend to form inclusion 
complexes of the type illustrated by Figure 1-2.  
 
Figure 1-2. Equilibrium binding of a drug with a cyclodextrin 
The driving forces for inclusion complexation are both enthalpic and entropic in nature 
and not fully understood. Although the ability of a drug molecule to ―fit‖ into the cyclodextrin 
torus is critical with the 6.0-6.5 Å opening of β-cyclodextrin being optimal for many 
biomedically relevant molecules, ―fit‖ by itself is not the only consideration. In forming 
inclusion complexes, the physical and chemical properties of both the drug molecule and the 
cyclodextrin molecule can be altered. Inclusion complexation has been used to solubilize, 
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stabilize and decrease the volatility of drug molecules. Additionally, it has been used to 
ameliorate the irritancy and toxicity of drug molecules. It might be argued that other techniques 
can achieve these same goals, so why use cyclodextrins? Most other excipients used to solubilize 
and stabilize drugs do so because of changes in the bulk properties of the resultant solvent. For 
example, co-solvents like various alcohols and glycols will increase the solubility of a poorly 
water soluble drug in a non-linear fashion with respect to co-solvent concentration. As illustrated 
in Figure 1-2, most drugs form 1:1 complexes with various cyclodextrins. This complexation can 
be defined by a binding constant K 1:1 and equation 1, where Drug]complex represents the 
concentration of drug in the complex form, [Drug]free represents the free drug concentration and 
[cyclodextrin]free represents the concentration of free cyclodextrin. 
 
In solubility considerations, if [Drug]free represents the solubility of a drug in the absence 
of a cyclodextrin, then the increase in solubility of a drug is largely driven by the product of K1:1 
and [Cyclodextrins]free, with [Cyclodextrin]free equal to [Cyclodextrin]total minus [Drug]complex. 
Since most values of K1:1 fall within the range of 100-20,000M
-1
 and [Cyclodextrin]total usually is 
less than 0.1-0.2 M, the maximum increases in solubility that can be expected from 1:1 
interactions with a cyclodextrins are in the range of 1,000 – 2,000. 36 
It is important to realize that the kinetics of inclusion complex formation and dissociation 
between a cyclodextrin and a drug molecule is fast. Where these events have been measured by 
various perturbation and competitive binding techniques, the half-lives for formation/dissociation 
are much less than one second and occur at rates very close to diffusion controlled limits with the 
complexes being continually formed and broken down. Inclusion complexation is a very 
13 
 
dynamic process and in no way does the complex species resemble a covalent species. For 
weakly bound drugs, dilution is sufficient to account for rapid and complete dissociation. For 
highly bound drugs, displacement of drugs by competing agents like plasma proteins and 
cholesterol may contribute to dissociation of the complex.  
1.8.1. Study of CD Complexation and Dilution Effects 
The most widely used approach to study inclusion complexation (Figure 1-3) is the phase 
solubility method described by Higuchi and Connors,
37
 which examines the effect of a 
solubilizer, i.e, CD or ligand, on the drug being solubilized, i.e, the substrate. Phase solubility 
diagrams are categorized into A and B types; A type curves indicate the formation of soluble 
inclusion complexes while B type suggest the formation of inclusion complexes with poor 
solubility. A BS type response denotes complexes of limited solubility and a BI curve indicates 
insoluble complexes. A-type curves are subdivided into AL (linear increases of drug solubility as 
a function of CD concentration), AP (positively deviating isotherms), and AN (negatively 
deviating isotherms) subtypes. β-CD often gives rise to B-type curves due to their poor water 
solubility whereas the chemically modified CDs like HP-β-CD and SBE-β-CD usually produce 
soluble complexes and thus give A-type systems. 
 
Figure 1-3: Phase solubility diagram 
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In the case of a 1:1 complex, using the following equation one can determine the 
equilibrium binding or association constant, K, from the slope of the linear portion of the curve. 
Ka : b   =   s l o p e / S0  ( 1   −   s l o p e )                      (2) 
where So is the intrinsic solubility of the drug studied under the conditions. 
1.8.2. Modified Cyclodextrins 
Two of the parent cyclodextrins, α- and β-cyclodextrin, are known to be parenterally 
unsafe due to severe nephrotoxicity. The etiology of the nephrotoxicity of both α- and β-
cyclodextrin is unknown but appears to be related to either cyclodextrin uptake by the kidney 
tubule cells followed by disruption of intracellular function, or the extraction of lipid membrane 
components by the cyclodextrin.  Modification of the parent cyclodextrins to improve the safety, 
while maintaining the ability to form inclusion complexes with various substrates, has led to the 
synthesis of random methylated β-cyclodextrin (RAMEB), 2-hydroxyprpoyl- β-cyclodextrin 
(HPBCD), sulfobutyl ether- β-cyclodextrin (SBECD) etc. These synthetically modified 
cyclodextrins have better solubility and excellent safety profile than the parent cyclodextrins. 
They have been used in parenteral formulations, oral, transdermal and ocular formulations. 
Synthetic cyclodextrins like RAMEB, HPBCD and SBECD are approved by regulatory agencies 
in USA and Europe. 
35,38
 
1.8.3. Factors Influencing Inclusion Complex Formation 
Type of CD can influence the formation as well as the performance of drug/CD 
complexes.
39-42
 For complexation, the cavity size of CD should be suitable to accommodate a 
drug molecule of particular size.
42-44
 Compared with neutral CDs, complexation can be better 
when the CD and the drug carry opposite charge but may decrease when they carry the same 
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charge.
45,46
 In general, ionic forms of drugs are weaker complex forming agents than their 
nonionic forms,
47
 but in the case of mebendazole, the un-ionized form was less included in HP-
β-CD than the cationic form.48  
Temperature changes can affect drug/CD complexation. In most cases, increasing the 
temperature decreased the magnitude of the apparent stability constant of the drug/CD complex 
and the effect was reported to be a result of possible reduction of drug/CD interaction forces, 
such as van der Waals and hydrophobic forces with rise of temperature.
46,49
 However, 
temperature changes may have negligible effect when the drug/CD interaction is predominantly 
entropy driven (ie, resulting from the liberation of water molecules hydrated around the charges 
of guest and host molecules through inclusion complexation).
45
  
Method of preparation, viz co-grinding, kneading, solid dispersion, solvent evaporation, 
co-precipitation, spray drying, or freeze drying can affect drug/CD complexation. The 
effectiveness of a method depends on the nature of the drug and CD.
44,50,51
  In many cases, spray 
drying,
52,53
 and freeze drying were found to be most effective for drug complexation.
54,55
  
When added in small amounts, water-soluble polymers or ion pairing agents enhance CD 
solubilizing effect by increasing the apparent complex stability constant. The polymers or ion 
pairing agents due to their direct participation in drug complexation, improve both 
pharmaceutical and biological properties of drug/CD complexes, independent of drug‘s 
physiochemical properties.
56-70
 Certain additives may compete with drug molecules for CD 
cavities and thus decrease the apparent complex stability constant, eg, additives with positive and 
negative hydrotropic effect.
71,72
 Though water structure forming agents added to CD solutions 
generally increase the total drug solubility, they showed opposite effects with 
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clotrimazole.
73
 Simultaneous complexation and salt formation with hydroxy carboxylic acid 
(HA) significantly increased the CD solubilizing power for a sparingly water-soluble amine type 
drug by forming drug/CD/HA multicomponent systems.
60,74
 Co-solvents can improve the 
solubilizing and stabilizing effects of CDs, eg, use of 10% propylene glycol in development of 
an oral itraconazole preparation containing 40% of HP-β-CD.75 Sometimes co-solvents may 
hinder drug complexation by competitive inclusion, eg, presence of 10% propylene glycol 
decreased the solubilizing effect of HP-β-CD for itraconazole. On dilution, the presence of 
propylene glycol favored absorption and precipitation of itraconazole in GI fluids and 
formulation by providing increased percentage of the free drug. The increased percentage of the 
free drug in presence of co-solvent was reported to be a result of lesser intrinsic solubility of the 
drug compared with the dilution concentration line at a given HP-β-CD concentration.76  
1.8.4. Effect on Drug Bioavailability 
CDs enhance the bioavailability of insoluble drugs by increasing the drug solubility, 
dissolution, and/or drug permeability. CDs increase the permeability of insoluble, hydrophobic 
drugs by making the drug available at the surface of the biological barrier, eg, skin, mucosa, or 
the eye cornea, from where it partitions into the membrane without disrupting the lipid layers of 
the barrier. In such cases it is important to use just enough CD to solubilize the drug in the 
aqueous vehicle since excess may decrease the drug availability.
77
 At low RAMEB 
concentrations, when hydrocortisone was in suspension, increasing the CD concentration 
increased the drug flux. At higher CD concentrations, when the drug was in solution, increasing 
the CD concentration decreased the flux. 
77
 It was found that addition of polymers can further 
enhance the drug permeability from aqueous CD solutions. Carboxy methyl cellulose (CMC) 
enhanced triclosan bioavailability from toothpastes containing β-CD by forming a 
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drug/CD/CMC complex with improved substantivity.
78
 CDs increased the bioavailability of 
lipophilic itraconazole from both an oral solution and an intravenous formulation by improving 
the drug solubility and absorption.
79
  
 
Figure 1-4: Penetration enhancement by CD’s through biological membrane 
1.8.5. Effect on Drug Stability 
CDs can improve the stability of several labile drugs against dehydration, hydrolysis, 
oxidation, and photodecomposition and thus increase the shelf life of drugs. It was reported that 
CD-induced enhancement of drug stability may be a result of inhibition of drug interaction with 
vehicles and/or inhibition of drug bioconversion at the absorption site.
80
 By providing a 
molecular shield, CD complexation encapsulates labile drug molecules at the molecular level and 
thus insulates them against various degradation processes. SBE-β-CD showed greater stability 
enhancement of many chemically unstable drugs than other CDs. 
Since the hydrolysis of drugs encapsulated in CDs is slower than that of free drugs,
81
 the 
stability of the drug/CD complex, ie, the magnitude of the complex stability constant, plays a 
significant role in determining the extent of protection. Very low concentrations of HP-β-CD 
(1% or lower), due to formation of a more physically unstable complex, did not protect taxol as 
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effectively as higher CD concentrations. The effect of complexation on drug stability can be 
represented by the following equation  
1/ k0   −   ko b s   =   1 / K c   ( k 0 − k c )   [ C D ]   +   1 / ( k 0 −   k c )    (3) 
where ko is the degradation rate constant of free drug, kobs is the observed degradation rate 
constant in the presence of CD, kc is the degradation rate constant of the drug within CD, Kc is 
the stability constant for the complex, and [CD] is the concentration of CD.
82
  
1.8.6. CD Applications in Oral Drug Delivery 
CDs enhance the mucosal drug permeability mainly by increasing the free drug 
availability at the absorptive surface.
83
 CD complexation can provide better and uniform 
absorption of low-soluble drugs with poor and erratic absorption and also enhance the drug 
activity on oral administration. CD complexation increased the absorption of poorly water-
soluble drugs, delivered via buccal or sublingual mucosa.
84,85
 Complexation of miconazole, 
econazole, and clotrimazole with HP-β-CD and genuine CDs increased the toxicity of these 
drugs on a human buccal cell culture model (TR146) by causing drug supersaturation.
85
 
Complexation can also mask the undesirable taste of drugs. Complexation with CDs suppressed 
the bitter taste of oxyphenonium bromide. With the assumption that only the free drug molecule 
exhibits bitter taste, the extent of the suppression was reported to be dependent on the availability 
of free drug, regardless of the kind and concentration of CD.
86
  
By the virtue of being able to form inclusion complexes with the drugs, CDs are known 
to enhance the solubility and protect the ester linkage of the compounds from hydrolysis. A vast 
amount of literature is published supporting the enhancement of bioavailability for oral 
formulations due to the inclusion complex formation with CDs. However, in very few cases the 
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absorption was hindered due to CD binding to the free drug and thus reducing its free 
concentration. In the process of inclusion complexation, the drug and CD are in dynamic 
equilibrium with each other leading to the inhibition of precipitation upon dilution up to a certain 
threshold. This phenomenon leads to the formation of supersaturated solutions of drug and CDs 
in the GIT with an enhanced absorption profile. In addition, the drugs can be lyophilized with the 
modified CDs to yield free-flowing powders. As a result, it was determined worthwhile to 
explore these advantages offered by CDs to develop an oral formulation for this ester prodrug of 
THC (THC-HS). The range of effects produced by CD complexation on absorption of water-
insoluble molecules is variable due to the chemical nature of the drugs, dose and drug: CD ratio. 
Hence it is difficult to predict a priori or create a generalized model of efficacy of CD with every 
drug molecule. Yet, it is important to understand the physical and chemical interactions of CDs 
with the individual drug molecule to predict the efficacy of the complexation process on that 
particular drug. Lyophilized solid dispersions CDs would be incorporated into polymeric 
transmucosal films where CDs were expected to increase the soluble fraction of free drug THC-
HS at the interface of the buccal membrane. Free THC-HS can then cross the buccal membrane 
into the plasma thus enhancing the bioavailability of THC through buccal route  
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1.9. Transmucosal Drug Delivery Systems  
Historical development of drug delivery through the oral cavity 
Historically, per-oral delivery has been the favored route of administration for the 
majority of therapeutic agents targeting systemic delivery. Oral administration generally leads to 
―transmucosal‖ absorption in the GI tract; however, this enteral route of delivery subjects 
compounds to extensive pre-systemic elimination, which may include GI degradation, 
metabolism or first pass clearance via the liver. This biotransformation has often resulted in low 
systemic bioavailability, short duration of therapeutic activity, and/or formation of inactive, and 
at times toxic metabolites.
87
 Parenteral routes, such as intravenous (IV) or intramuscular (IM) 
administration, unlike oral delivery, permit therapeutic agents to gain direct entry into the 
systemic circulation and therefore reach the intended site of action more rapidly (with total 
bioavailability achieved in many IV cases). Unfortunately, such a mode of drug administration 
entails certain health risks, requires specialized equipment, often requires close medical 
supervision of the medication or may even necessitate the hospitalization of patients during 
treatment. 
Systemic transmucosal delivery of therapeutic agents via the epithelium lining of 
accessible body cavities such as the oral cavity (mouth), nose, rectum and vagina have received 
renewed interest within the last decade. These routes have numerous advantages over their per-
oral counterpart such as bypassing hepatic first pass clearance and therefore potentially 
improving systemic bioavailability. In addition, these transmucosal routes may eliminate the 
disadvantages of IV and IM administration. As a result, nasal
88-92
, rectal
93-96
 and vaginal
97,98
 
routes of delivery have gained the attention of many researchers.  
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The intraoral drug delivery sites are distinguished on the basis of their placement on the 
particular area in the oral mucosa. Two main type of transmucosal drug delivery routes are: 
1. Buccal: Placed on inner side of the cheek mucosa or Gum area on the teeth 
2. Sublingual : placed on the sublingual mucosa 
Although the rectal, vaginal and ocular mucosa possess various advantages to drug 
delivery, poor patient acceptability associated with these sites makes them feasible at best for 
local drug delivery.  The oral cavity, however, is a highly accepted route for both local and 
systemic drug delivery.
99
  Indeed, transmucosal delivery via the oral mucosa is increasingly 
being considered to be the preferred route for many drug classes.  
Technological advances in biomaterials and techniques have resulted in the formulation 
of designs germane to the oral cavity while tailoring the challenges of the physicochemical 
properties of the drug entity itself to achieve the drug delivery system‘s therapeutic aims.  
Strategically, these systems must address one or more of the following:  1. attain rapid release 
and absorption; 2. sustain the release and/or duration of the absorption process; 3. develop 
bidirectional or unidirectional systems; and 4. fabricate patient-friendly oral mucosal delivery 
systems.  Indeed, patient compliance has recently shifted the trend towards the need for once a 
day dosing regimens and convenience. This has advocated the investigation of drugs with high 
potency and sustained effect (e.g. Peptide drugs).  However, due to the advantages of delivering 
a drug through the oral mucosa, these drugs are viable candidates for delivery via this route. 
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1.9.1. Oral cavity 
The Mucosa 
When selecting drug candidates for incorporation into dosage forms for oral transmucosal 
drug delivery, one must be cognizant of the physicochemical properties of the drug molecule and 
their effect on absorption.  However, the anatomy and physiology of the intended site for 
delivery also need to be recognized and evaluated.    
 
Figure 1-5: Structure of oral mucosa 
General Mucosal Variation 
All covering and lining tissues of the body consist of a surface epithelium supported by a 
fibrous connective tissue.
100
 Upon comparing the structure of skin and oral mucosa to that of the 
GI tract, a major difference becomes apparent in the organization of the epithelium, which 
23 
 
reflects the different functions of these regions. The lining of the stomach, and the small and 
large intestine consist of a simple epithelium. However, skin and oral mucosa are covered by a 
stratified epithelium composed of multiple layers of cells, which show various patterns of 
differentiation between the deepest cell layer and the surface (Figure 1-5). This type of 
differentiation reflects the functional purposes and demands exerted on the tissue, such as 
mobility or rigidity and resistance to mechanical damage.   
Regional Variation in the Oral Mucosa   
In general, three different types of oral mucosa are recognized:  1. the masticatory 
mucosa; 2. specialized mucosa; and 3. the lining mucosa.  Masticatory mucosa covers the 
gingiva and hard palate, which are regions that are subjected to the mechanical forces of 
mastication.  This tissue consists of a keratinized epithelium that resembles the epidermis of the 
skin and is usually tightly attached to underlying structures by a collagenous connective tissue. 
Specialized mucosa, with characteristics of both masticatory and lining mucosa, is found on the 
dorsal of the tongue. It has a surface consisting of areas of both keratinized and non-keratinized 
epithelium, which is tightly bound to the underlying muscle of the tongue. 
The lining mucosa of the oral cavity is covered by a stratified, squamous epithelium that 
is non-keratinized.  This lining mucosa epithelium is located within the cheek (buccal), soft 
palate (palatal), part of the tongue (lingual), the floor of the mouth (sublingual), and the alveolar 
lining mucosa (labial mucosa).  The buccal, labial and sublingual tissue are primary targets for 
drug delivery due to their potential permeability.  Figure 1-5 illustrates these anatomical 
locations within the oral cavity as well as their mucosal type. Although the surface area of the 
oral mucosa is relatively small in comparison to the skin and the GI tract, its high vasculature 
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lends itself to potential drug access.  As discussed previously, compounds that enter via the oral 
mucosa directly access the systemic circulation, thus avoiding first pass metabolism.  Blood flow 
through the oral mucosa is abundant, and thus this factor is not considered a rate limiting step for 
drug absorption. 
In a recent study comparing two types of oral mucosal absorption routes, Artusi et al
94
 
designed two thiocolchicoside dosage forms, one for sublingual and the other for buccal 
delivery.  The buccal site demonstrated slower drug absorption than the sublingual route, 
however formulation bioadhesivity to the buccal site suggested that this was more suitable for 
sustained drug release.  Thus, regional mucosa variation may be exploited for achieving oral 
transmucosal delivery objectives. 
1.9.2. Advantages and challenges of the buccal drug delivery  
The membranes that line the oral cavity are readily accessible, robust and exhibit fast 
cellular recovery following local stress or damage. Indeed, the oral cavity is very used to being 
exposed to various exogenous compounds.  Properly constructed oral transmucosal drug delivery 
(TMD) systems are easy and painless to administer and well accepted by the patient. Precise 
dosage form localization is possible and there is the ability to terminate delivery when required 
(e.g. toxicity).  Patients could conceivably control the period of administration, in addition to the 
desired therapeutic effect. From a formulation point of view, the thin mucin film that exists on 
the surface of the oral cavity provides the pharmaceutical scientist with the opportunity to retain 
delivery systems in contact with the mucosa for prolonged periods with the help of 
mucoadhesive compounds. Such a system would be in close contact with the absorbing 
membrane, thus optimizing the drug concentration gradient across the biological membrane and 
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reducing the diffusional pathway. Therefore, the oral transmucosal route is considered a potential 
route not only for rapid onset, but also for controlled or sustained systemic delivery. 
For example, melatonin is a hormone secreted primarily by the pineal gland in a circadian 
fashion and acts as a synchronizer of biological rhythms in several animal species including 
humans.  Because of the short half-life and poor oral bioavailability characteristics of melatonin, 
it is not a good candidate for conventional oral immediate-release delivery. A sustained- or 
controlled-release delivery system for melatonin with rapid onset and rapid offset may be 
necessary to mimic the normal endogenous plasma melatonin profile.  Benes et al
101,102
 evaluated 
the effect of oral controlled-release (CR), oral transmucosal (buccal, TMD) and transdermal 
(TDD) drug delivery systems on plasma concentrations of melatonin and its principal metabolite 
in human subjects.  Inter-subject plasma concentrations of melatonin were significantly variable 
following both oral CR and TDD. TMD provided prompt systemic drug levels with less 
variability than oral CR or TDD delivery. Also, plasma melatonin levels fell promptly and 
rapidly after removal of the patch.  These investigators concluded that the oral transmucosal 
route was able to mimic the physiological plasma profiles of both melatonin and its principal 
metabolite. 
Disadvantages of transmucosal drug delivery entail an enzymatic barrier
103
 and the 
physiology and histology of the various mucosa. The former leads to the degradation of peptides 
and proteins and the latter prevents the transport of large molecules. However, tailoring the 
formulation of oral transmucosal drug delivery systems to include enzyme inhibitors, when 
appropriate and permeation enhancers may minimize or eliminate these barriers.  Thus, the 
numerous advantages of oral transmucosal delivery must continue to be explored for potential 
delivery of inorganic and organic agents for local as well as systemic therapeutic effects. 
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1.9.3. Factors Affecting Drug Absorption from the Oral Mucosa 
Until the mid-1980s, only a handful of drugs were regarded to be feasible, or even 
clinically necessary, for delivery via the oral mucosal route. However, new and more potent 
drugs, and improved biomaterials have provided a renaissance for this route of delivery.  In 
addition, with research in the transdermal area, it was demonstrated that certain penetration 
enhancers may be effective in improving the permeability of oral mucosal tissue, coupled with 
more appropriate delivery system designs (buccal patches, films).  It therefore became necessary 
to understand the biological and physicochemical nature of the drug absorption process and the 
mechanism(s) of drug penetration across this tissue at the cellular and molecular level.  The three 
main factors that influence drug absorption from the mouth entail the physicochemical properties 
of the drug, biological factors of the oral cavity and formulation factors of the drug delivery 
system. 
Physicochemical Factors 
Passive diffusion is the primary mechanism involved in drug permeation across the oral 
mucosa.  Facilitated diffusion has also been shown to occur primarily with nutrients.  The 
phenomenon of ―buccal partitioning‖ has been used to describe the membrane reservoir effect 
noted in some studies.
104-107
  However, this drug binding effect has not been well identified to 
date.  Parameters such as partition coefficient (Kp), degree of ionization and molecular weight of 
the drug itself are of paramount importance for drug delivery across the oral mucosa membrane.  
The extent of oral mucosal absorption is generally proportional to the drug‘s lipophilicity or oil-
in-water partition coefficient.  However, there is a delicate balance between Kp and solubility for 
a drug to be a successful candidate for oral mucosal absorption.
108
  For example, if a drug is too 
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lipophilic, it cannot dissolve appreciably in the aqueous mucin/saliva and thus may not be 
available for significant absorption.  Therefore, potency of the drug must be considered when 
choosing an appropriate drug candidate for a transmucosal delivery system.     
Generally, the unionized form of a drug is considered to be the most lipid-soluble and 
thus most diffusible across biological membranes.  Therefore, pKa of the drug must be addressed 
when diffusivity and ultimate bioavailability for a therapeutic agent are being considered.  The 
average pH of human saliva is approximately 6.4 and the importance of pH on drug absorption 
via the oral mucosa has been studied extensively.  Although most of these studies illustrate the 
importance of the state of drug ionization, the pH of saliva remains relatively constant.  Thus the 
pKa of a weak acid or a weak base ultimately is the deciding factor as to the degree of drug 
ionization.  In general, small molecules penetrate the mucosa more rapidly than larger molecules.  
However, concerning molecular weight, it should be noted that inclusion of penetration 
enhancers has dramatically improved the permeability of some high molecular weight 
mucopolysaccarides.
109
 
Biological Factors   
Saliva may be considered a positive or a negative factor for oral transmucosal drug 
absorption. It has been reported that adult males have an average volume of approximately 0.9 
mL and females a slightly smaller average volume of about 0.8 mL.
109,110
 Studies of salivary 
secretions have established that mucins together with other groups of salivary proteins such as 
proline-rich proteins, histatins, cystatins, statherins and α-amylases protect the integrity of the 
hard and soft oral tissues. Changes in both the volume and composition could alter the 
permeability of the mucosa.  The salivary ‗component‘ is important in that drug absorption 
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occurs more readily across moist mucous membranes than those that lack mucous.
111
  Also, a 
drug must dissolve before absorption can occur—and in TMD systems the dissolution medium is 
aqueous mucin/saliva.  But excess saliva has been shown to adversely affect absorption for some 
systems.  On the other hand, disease states or other drugs that the patient may be taking may 
cause xerostomia and again may inhibit drug permeation due to decreased salivary flow.  These 
factors may in turn affect the condition of the mucosa, which may cause an increase or decrease 
in drug penetration.   
A limiting factor for oral mucosal drug delivery is the area to which the delivery system 
may be applied in the oral cavity.  
It is generally agreed that the oral mucosa tissue is more permeable to drugs than the 
skin.  The extent of differences in permeability, however, is widely debated.  These estimates in 
the literature range from a 4-fold to a 4000-fold greater permeability for the mucosa.
112
  Such 
wide differences partially lie in the fact that different regions of the mucosa exhibit different 
structures and thus different permeability.  It is also generally accepted that the permeability 
‗barrier‘ exists in the outermost one-fourth to one-third of the mucosal epithelium.  This barrier 
has been proposed to result from intercellular material that is derived from membrane coating 
granules (MCGs).
96
    In keratinized epithelia these intercellular lipid substances include 
sphingomyelin, glucosylceramides, ceramides and other non-polar lipids.  Unkeratinized 
epithelia contain primarily cholesterol esters, cholesterol and glycosphingolipids.  Studies have 
demonstrated that the MCGs resulting decrease in permeability and keratinization alone may not 
play a significant role in the permeability barrier. Due to other factors discussed previously, a 
primary strategy for transmucosal drug delivery should be to target the oral cavity‘s lining 
mucosa.
113
 Oral mucosal anatomy suggests that there are two permeability barriers. The 
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intercellular spaces and cytoplasm are essentially hydrophilic in nature and function as a 
transport barrier for lipophilic compounds.  The second barrier is the cell membrane, which is 
lipophilic and impedes diffusion of hydrophilic compounds due to a low partition coefficient.  
The coexistence of these two regions in the oral mucosa suggests two possible routes for drug 
transport:  paracellular (intercellular) and transcellular (intracellular). Drug transport by these 
two routes most likely occurs simultaneously, although one route usually dominates depending 
on the physicochemical properties of the diffusant.  It is believed by some researchers that the 
paracellular route is the primary route for hydrophilic compounds, and thus, the intercellular 
space is the preferred route for hydrophilic drug transport.  Limited surface area of the 
intercellular space and the labyrinthal pathways within this area are the main limitations for this 
route. The flux of a drug candidate in this route (JH) may be written as:
114
                            
                              JH =   DH  CD / hH                                           (4) 
where  is the fraction of surface area of the paracellular route, DH is the diffusion 
coefficient of the intercellular spaces, hH is the path length of the paracellular route and CD is the 
donor side drug concentration. 
The cell membrane is relatively lipophilic in nature and thus for lipophilic compounds the 
partition coefficients are high.  Also, the surface area for the transcellular route is large and the 
pathways for transcellular movement is relatively short, thus it is believed that the permeability 
of lipophilic compounds across the epithelial cell membrane is typically high. The flux of drug 
movement in the transcellular route (JL) can be expressed as: 
JL =  (1-) DL KP CD / hL                                (5) 
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where KP is the partition coefficient between the lipophilic region (cell membrane) and 
the hydrophilic region, hL is the path length of the transcellular route.  Regardless, one should 
keep in mind that the primary route of transport is that which provides the least resistance to 
penetration of an individual drug molecule. 
1.9.4. Requirements for a Transmucosal Drug Delivery System—Formulation 
Factors 
Bioadhesion and Bioadhesive Polymers 
Bioadhesion is a phenomenon related to the ability of biological or synthetic material to 
adhere to a biological substrate. Oral mucosal drug delivery necessitates the use of mucoadhesive 
polymers as these dosage forms should ideally adhere to the mucosa and withstand salivation, 
tongue movement and swallowing for a predetermined period of time.  As one would expect, this 
concept has received considerable attention in the pharmaceutical field due to the potential for 
applications in drug delivery. A widely used approach to explain the adhesive properties of drug 
delivery systems is based on the belief that interatomic or inter-molecular forces are established 
at the interface of the adhesive and the substrate. Numerous mechanisms of adhesion or 
mucoadhesion have been established and proposed. These include hydrogen bonding, surface 
energy and contact angle considerations, polymer chain interpenetration, and the swelling rate of 
a polymer interacting with mucin.
115-117
 Adequate bioadhesion is essential for the success of a 
bioadhesive drug delivery system such that controlled release is attained to elicit the desired 
therapeutic response. Examples of mucoadhesive polymers that have been investigated are 
Carbopol, POLYOX™ etc. 
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Several techniques for in-vitro determination of bioadhesion have been reported, which 
include tensile testing, shear stress testing, adhesion weight method, fluorescent probe method, 
flow channel techniques and a colloidal gold staining method. More recently, Texture Analyzer® 
(TA.XT2i) has been used for mucoadhesive studies. Some of the texture analyzer variables that 
may be used to assess a transmucosal system‘s bioadhesion are contact force, contact time and 
speed of probe withdrawal from the chosen substrate.
118,119
 
Penetration Enhancement of the Oral Mucosa 
Though the oral cavity has been used as a site for systemic drug delivery, the amount of 
drug absorbed via this route has historically been problematic for the attainment of a desired 
therapeutic response. As discussed previously, this is due in part to the relatively small surface 
area of the oral mucosa and, more importantly, relatively low tissue permeability to various 
therapeutic agents. Unlike surface area, which is relatively constant, permeability of the oral 
mucosa may be temporarily altered to allow a greater drug flux and thus increased 
bioavailability.
120,121
  Such an increase in drug permeability via the oral epithelium has been 
demonstrated in several studies by the use of chemical penetration enhancers.
121-125
   
An ideal chemical penetration enhancer would possess the following properties:  1. Non-
toxic, non-irritating, non-allergenic; 2. Immediate onset of increased permeability; 3. Immediate 
recovery of the normal barrier properties when removed; and 4. Physically and chemically 
compatible with a wide range of drugs.  It is not surprising that such an ideal enhancer has not 
been discovered to date.  An improved understanding of enhancer structure and mechanism of 
action is extremely important for formulation choices of transmucosal systems.  In general, 
penetration enhancers are thought to function in one or more of the following manners:  
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Fluidizing intercellular lipids, altering protein conformation and/or modifying drug solubility 
parameters.
123,124
  In a formulation, judicious use of a combination of enhancers may provide a 
synergistic impact on membrane permeability while minimizing individual enhancer 
concentration and thus decreasing tissue toxicity (irreversibility).  A study of current penetration 
agents coupled with the discovery of novel agents will lead to a new era in oral mucosal drug 
delivery systems.  Also a continued and intensified effort is needed to thoroughly explore the 
enhancer agents currently available.   
 Enzyme Inhibitors 
A majority of the protein and peptide degradation events that occur in the GI tract revolve 
around the resident proteases and peptidases (e.g. pepsin, chymotrypsin, elastase, 
carboxypeptidase, aminopeptidase).
126,127
  Although buccal mucosa is relatively low in 
enzymatic activity as compared to other mucosa, there is still potential for degradation of drugs 
delivered via the intra-oral transmucosal route.  This transformation is particularly true for 
peptide/protein drugs due to the presence of enzymes in the saliva and mucosa. Therefore, this 
enzymatic activity may act as a barrier to drug transport that limits the absorption of drugs across 
the tissue. Walker et al.
126
 evaluated the peptidase activity on the surface of porcine buccal 
mucosa in vitro and reported that, while aminopeptidase N activity was detected using Leu-p-
nitroanilide, no carboxypeptidase or dipeptidyl peptidase IV activity was detected on the buccal 
mucosa. In such cases, enzyme activity can be minimized by the co-administration of enzyme 
inhibitors (e.g. bacitracin, aprotinin, diprotin-A) to improve the bioavailability of drugs via 
buccal delivery.  Langoth
127
 , Yang
128,129
 , Bird
130
 and Garren
131
  have demonstrated the role of 
enzyme inhibitors in their respective studies 
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1.9.5. Oral Transmucosal Dosage Forms 
Conventional Dosage Forms for Oral Transmucosal Delivery 
Solutions and various types of tablets, including fast dissolving tablets, are conventional 
dosage forms that have been adapted for oral transmucosal use. The primary focus of these 
delivery systems is to rapidly create high drug concentrations within the mouth and make the 
therapeutic agent available to a relatively large mucosal surface. These dosage forms are 
generally easy to manufacture since standard manufacturing techniques may be utilized. 
However, several formulation and physiological factors may make their performance as oral 
mucosal delivery systems less than optimal for both rapid and sustained drug delivery. These 
factors may include: 1. short residence time of such formulations as they may be removed by 
swallowing; 2. high inter- and intra-individual variability in bioavailability; and 3. the released 
drug is not protected from the environment and therefore subject to its influences. In addition, 
following administration of these dosage forms, the drug concentration falls rapidly due to 
extensive dilution by saliva and the resultant swallowing of the drug by the patient. Therefore, 
the formulations that balance the rate of drug release with the rate of drug absorption for the 
attainment of controlled or pre-determined drug delivery are necessary. The system must be of a 
surface area and thickness acceptable to the patient while containing and releasing sufficient 
drug for the desired therapeutic activity. It has been reported that intra-oral patches having a 
surface area of 0.5 to 1 cm
2
 are comfortable and patient-friendly, although larger patches may be 
tolerated. Convenient, patient friendly transmucosal thin films can be prepared by various 
methods such as solvent casting and hot-melt extrusion. Films prepared by hot-melt extrusion 
have definite advantages of being pliable and strong. 
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1.10. Hot-Melt Extrusion: 
Hot-melt extrusion (HME) is the process of pumping raw materials with a rotating screw 
under elevated temperature through a die into a product of uniform shape.  Although used for 
over half a century in the plastics industry, interest in HME techniques for pharmaceutical 
applications is growing rapidly with well over 100 papers published in the scientific literature in 
the last 12 years.  Also, the number of HME patents issued for pharmaceutical systems has 
steadily increased since the early 1980‘s with international scope (Figure 1-6).132  Within the 
chart below, the US and Germany hold approximately 28% of the patents each, while Japan 
makes up about 19% of the total.  
 
Figure 1-6: Patents for hot-melt extrusion 
HME offers many advantages over other pharmaceutical processing techniques. Molten 
polymers during the extrusion process can function as thermal binders and act as drug depots 
and/or drug release retardants upon cooling and solidification.  Solvents and water are not 
necessary thereby reducing the number of processing steps and eliminating time-consuming 
drying steps. A matrix can be massed into a larger unit independent of compression properties. 
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The intense mixing and agitation imposed by the rotating screw cause de-aggregation of 
suspended particles in the molten polymer resulting in a more uniform dispersion.  The process is 
thus continuous and efficient. 
It has been estimated that as many as 40% of all new molecular entities have poor 
bioavailability because of low aqueous solubility. This percentage is likely increasing due to the 
advent of combinatorial chemistry and the importance of lipophilic receptors. Formulation of 
such compounds for oral delivery presents one of the most frequent and formidable challenges to 
formulation scientists. HME has been used to improve the bioavailability of drug substances 
especially those having low water solubility by formation of molecular dispersions.
133-137
 
HME requires a pharmaceutical grade polymer that can be processed at relatively low 
temperatures due to the thermal sensitivity of many drugs.  All components must be thermally 
stable at the processing temperature during the short duration of the heating process. Although 
this requirement may sometimes limit a pharmaceutical compound from HME processing, input 
of new techniques and equipment specifications over the last decade have expanded the list of 
actives not previously thought to be applicable for this emerging technology. Table 1-1 
summarizes the advantages and disadvantages of HME.  
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Table. 1-1:  Advantages and Disadvantages of Hot-Melt Extrusion Processing 
Advantages Disadvantages 
 HME is a potential ―continuous 
process‖ 
 May not be applicable for heat labile 
drugs (such as proteins, peptides, etc.) 
 No organic solvents or water are 
needed 
 Must be relatively moisture free 
 Less labor and equipment demands  Non-traditional equipment and requires 
education and training 
 Shorter and more efficient processing 
times 
 
 Favorable product cost  
 Can produce ―solid solutions or 
dispersions‖ which may lead to 
improved solubility and bioavailability 
 
 Product life-cycle management  
 
1.10.1. Equipment, Principles of Extrusion and Process Technology 
HME Equipment: Pharmaceutical-class extruders have evolved and adapted to mix 
drugs with carriers for various solid dosage forms as well as for the production of wet 
granulations. The major differences between a plastics extruder and a pharmaceutical-class 
extruder are the contact parts, which must meet regulatory requirements.  Typically, the 
metallurgy of the contact parts must not to be reactive, additive or absorptive with the product. In 
addition, the equipment is configured for the cleaning and validation requirements associated 
with a pharmaceutical environment. For example, some pharma extruders offer a ‗clam shell‘ 
design for ease of access to the screw.  Also, HME research at the lab scale has lead to the 
development of ‗mini‘ extruders so that feasibility studies may be performed on small quantities 
of polymers and APIs. Otherwise, the unit operations performed for a pharmaceutical product is 
virtually identical to a plastics extrusion process. 
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Types of Extruders and Screw Design:  Most pharmaceutical extrusion applications 
utilize ‗screw extrusion‘ rather than ram extrusion due to better control of temperature profiles 
and product homogeneity. Thus unlike ram extrusion, a screw extruder provides more shear 
stress and intense mixing.  At a minimum, a screw extruder consists of three distinct parts: a 
conveying system for material transport and mixing, a die system for extrudate formation and 
downstream auxiliary equipment for cooling, cutting or collecting the extruded product. 
Individual components within the extruder are the feed hopper, a temperature controlled barrel, a 
rotating screw, die and heating and cooling systems. Standard process control and monitoring 
devices include zone temperature and screw speed with optional monitoring of torque, drive 
amperage, pressure and melt viscosity. Temperatures are normally controlled by electrical 
heating bands, and monitored by thermocouples.  Basically, there are two types of screw 
extruders: 1) Single screw and 2) Twin screw 
The single screw extruder is the most widely used extrusion system in the world 
(especially for plastics). One screw rotates inside the barrel and is used for feeding, melting, 
devolatilizing and pumping.  However, once screws are reduced to less than 18 mm, the screw 
becomes weak and solids transportation is far less reliable. To overcome these shortcomings, a 
vertical screw, driven from the discharge end, may be used.  
Twin-screw extruders, employed increasingly in pharma applications, utilize two screws 
usually arranged side by side. The use of two screws allows a number of different configurations 
to be obtained and imposes different conditions on all zones of the extruder, from the transfer of 
material from the hopper to the screw, all the way to the metered pumping zone.
138
 In a twin-
screw extruder, the screws can either rotate in the same (co-rotating extruder) or the opposite 
(counter-rotating extruder) direction. Generally, counter-rotating twin-screw extruders suffer 
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from disadvantages of potential air entrapment, high-pressure generation, and low maximum 
screw speeds and output, and are thus not used routinely for pharma applications. Co-rotating 
twin-screw extruders on the other hand are generally of the intermeshing design, and are thus 
self-wiping.
139
 They are industrially the most important type of extruders and can be operated at 
high screw speeds and achieve high outputs, while maintaining good mixing and conveying 
characteristics. Twin-screw extruders have several advantages over single screw extruders, such 
as easier material feeding, high kneading and dispersing capacities, less tendency to over-heat 
and shorter transit time.  
In an extrusion process, the dimensions of the screws are given in terms of L/D ratio, 
which is the length of the screw divided by the diameter. Typical extrusion process lengths are in 
the 20 to 40:1 L/D range, or longer.  Extruder residence times are generally between 5 seconds 
and 10 minutes, depending upon the L/D ratio, type of extruder, screw design and how it is 
operated. The size of an extruder is generally described based on the diameter of the screw used 
in the system, i.e., 16 – 27 mm extruder (pilot scale) as compared with a 60 mm extruder 
(production scale).
140
 The screw is typically divided into three sections along the length of the 
barrel: feeding, melting or compression, and metering. The die is attached at the end of the 
barrel.  The shape of the die dictates the physical form or shape of the extrudate.  A wide variety 
of downstream systems are available following the extrusion process.  Pellets or shapes may be 
extruded and wound or cut-to-length. Co-extrusion allows the possibility of complex properties 
from a single structure, which can be beneficial for time-release products.  Film and lamination 
systems are used to combine melt extrusion with substrates for transmucosal and transdermal 
applications. For film applications, chill rolls and torque winders are used to rapidly cool and 
collect the extrudate.  Film thickness can be adjusted by changing the die opening, the mass flow 
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rate introduced into the extruder, screw speed, the rotation speed of the chill rolls, or the torque 
winder.  
The efficiency of the melting process depends on the polymer properties and the extruder 
design. Thermoplastic polymers primarily exist in a molten state when entering the metering 
section.  The mass flow rate of the extrudate is highly dependent upon the channel depth and the 
length of the metering section.  In general, polymers with low melt viscosities and high thermal 
conductivities exhibit a more efficient melting process. Changes in the screw design are 
sometimes warranted to improve the melting process and improve mass flow through the 
extruder.  Solidified polymer components can block the channel if melting is incomplete and 
result in a surge of material around the blockage. Differential scanning calorimetry, 
thermogravimetric analysis and gel permeation chromatography are often used to monitor 
polymer stability. Plasticizers, antioxidants, thermal lubricants and other additives are often 
included in the formulation to address stability issues. 
1.10.2. Applications of HME 
In recent years, several research groups have demonstrated HME as an innovative and 
viable approach to produce various pharmaceutical drug delivery systems in the field of 
formulation such as pellets
141,142
, granules
143-145
, immediate and modified release tablets
146,147
, 
oral fast dissolving systems
148
, transdermal and transmucosal delivery systems
149-151
, transungual 
delivery systems.
152
 
HME technology has proved its potential in producing various solid dosage forms, 
providing the flexibility to modify drug release as required. This part of the article will focus on 
various HME applications in drug delivery through oral, transdermal, transmucosal, transungual, 
and other routes of administration.   
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Oral Drug delivery: A United States patent, McGinity et al.
145,153,154
 has disclosed a novel 
method of preparing effervescent granules utilizing hot-melt extrusion techniques.  The granules 
were prepared by hot-melt extruding an acidic and an alkaline agent coupled with a hot-melt 
extrudable binder (melting/softening point temperature less than 150°C), which was capable of 
forming a eutectic mixture with the acidic agent. The granules thus produced demonstrated a 
controllable rate of effervescence. Additionally, hot-melt extrusion has been utilized to enhance 
the dissolution rate of the actives by preparing solid dispersions for immediate and sustained 
release applications. Sun Yunzhe et al. prepared a semi-solid capsule containing nimodipine 
solid dispersion prepared by HME technology. The bioavailability study of this HME 
formulation in the capsule conducted in beagle dogs exhibited similar bioavailability to a 
referenced product. However, time to reach peak concentration was much faster for the HME 
product than the reference formulation. In this study authors have demonstrated that the 
combination of a solid dispersion technique and semi-solid filling into the capsule not only 
produced a rapid and pH-independent release of the drug, but also prevented recrystallization of 
the drug in the matrix.
155
 The above examples illustrate the fact that the choice of excipients is of 
utmost importance in designing HME dosage forms with fast or immediate release 
characteristics.  
Controlled Release : Fukuda, Peppas and McGinity investigated the influence of sodium 
bicarbonate on the physicochemical properties of controlled release HME tablets containing 
ammonio methacrylate copolymer, Type B (MAC RS PO) and/or amino methacrylate copolymer 
(MAC
 
E PO).
156
 In this study, acetohydroxamic acid and chlorpheniramine maleate were used as 
the model drugs. The authors studied the drug release properties and buoyancy in the dissolution 
media for both HME and directly compressed (DC) tablets by incorporating sodium bicarbonate 
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into the tablet. The HME tablets prepared from the powder blend containing both MAC RS PO 
and sodium bicarbonate demonstrated sustained release properties. In addition, the tablets floated 
on the surface of the dissolution media for up to 24h. The cross-sectional morphology of the hot-
melt extruded tablets exhibited a porous structure, reportedly due to carbon dioxide gas 
generation resulting from thermal decomposition of sodium bicarbonate in the softened acrylic 
polymers at elevated temperature during processing. On the contrary, the DC tablets exhibited 
rapid drug release in the dissolution media and did not demonstrate any buoyancy. The drug 
release rate from floating HME tablets was controlled by both the incorporation of MAC E PO 
into the matrix tablet and the diameter of the die utilized in the extrusion equipment.    
1.10.3. HME and Advanced Technologies 
In the recent decade, drug particle engineering, utilizing nanotechnology, has gained 
much interest to improve the solubility limitations of poorly soluble drug compounds. However, 
it is associated with several limitations such as particle aggregation, morphological instability, 
and poor wettability. Miller and co-workers demonstrated the suitability of HME as a novel and 
viable approach for nanoparticle engineering by overcoming the above mentioned limitations.
157
 
The focus of this investigation was to elucidate whether the shear generated during extrusion 
would deaggregate and disperse the micronized particles into a hydrophilic polymer matrix, 
without solubilizing or altering the properties of the drug particles. The concept was evaluated by 
developing itraconazole (ITZ)-polyvinyl pyrrolidone (PVP) and ITZ-hydroxypropyl methyl 
cellulose (HPMC) microparticles, subsequently dispersed in a polymer carrier system composed 
of poloxamer 407 and polyethylene oxide (PEO)-200M (7:3 ratio) utilizing a melt extrusion 
technique. From SEM imaging, authors have provided visual confirmation and demonstrated that 
HME did not alter the morphology of the engineered particles and that they were homogeneously 
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dispersed within the polymer carrier system. Moreover, drug release studies performed revealed 
that the dissolution rate of the micronized particles was improved by HME due to particle 
deaggregation and enhanced wetting. However, the selection of a carrier system and optimization 
of operating conditions during the extrusion process were considered the critical steps utilizing 
this methodology. It was determined that the two extruded formulations performed similarly in 
their in vivo rat model, per oral dosing, as confirmed by their statistically similar AUC values 
1.10.4. HME and Transmucosal Drug Delivery 
Transmucosal delivery is particularly advantageous for poorly-water soluble drugs and 
those which undergo extensive first-pass metabolism. Repka and co-workers extensively 
investigated the hot-melt extrusion technique as an incisive means for developing numerous 
formulations containing various drug molecules for delivery through the buccal route.
152,158-161
 
Polymeric films intended for oral or transmucosal delivery should be flexible, elastic and 
soft, yet sufficiently bioadhesive to withstand the mechanical stress of the oral cavity. Prodduturi 
et al. developed clotrimazole (CT) polymeric films utilizing different molecular weights of 
hydroxypropyl cellulose (HPC- JF, GF and MF) and polyethylene oxide (PEO N-80 and PEO N-
750).
162
 Both the polymeric systems exhibited zero order drug release and release rate was 
dependent on the molecular weight of the polymer. The drug release rate constant and release 
mechanism were independent of % of drug loading. Thus, size of the dosage form and/or release 
of the drug from extruded film could be tailored by altering the drug load without affecting 
release mechanism. Also, it was determined that at a minimum of a 55:35 ratio of polymers 
(HPC/PEO) produced optimal long term stability of the API. These data are obviously germane 
for the development of successful controlled release dosage forms. Influence of physico-
mechanical properties of vitamin E TPGS, an amphiphilic molecule, as a formulation additive on 
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the properties of hydrophilic films was studied by Repka and McGinity.
160
 Vitamin E TPGS 
functioned as a plasticizer since a linear decrease in glass transition temperature of the films, 
containing either a 50:50 or 80:20 ratio of HPC to PEO, with increasing concentrations of 
Vitamin E TPGS (1, 3, and 5%) was observed. The reported effect was comparable to other 
conventional plasticizers. In addition, vitamin E TPGS was found to be an excellent processing 
aid, by decreasing barrel pressure, drive amps, and torque of the extruder. 
1.11. Conclusion 
Hot-melt extrusion technology is an increasingly attractive process for the manufacture of 
various drug delivery systems. The literature published in this field so far reveals many 
interesting aspects such as fast dispersing systems, floating systems, complex formation within 
the melt, and nanoparticle engineering combined with melt extrusion technology. Many of the 
pharmaceutical products prepared utilizing this technique has been approved in the United 
States, Europe, and Asia. The drug being embedded in the carrier matrices as a solid 
dispersion/solution may allow for sustained or controlled release applications and dissolution 
rate improvement. Moreover, improved bioavailability has been achieved which demonstrates 
the value of HME as a powerful drug delivery technology. Although several researchers have 
been successful in employing HME to formulate many thermolabile molecules, exploitation of 
innovative pharma equipment design, new custom designed polymers and novel processing 
approaches continues for the development of even more efficient drug delivery systems. Due to 
the advantages offered by HME, it will be employed as a primary technology to produce hot-
melt polymeric transmucosal films of THC-HS. 
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CHAPTER 2 
Goals and Objectives 
  
45 
 
With the potential problems associated with transmucosal delivery of THC-HS in mind, 
the main objectives of this research are: 
Chapter 3: To develop novel solid dispersions of THC-HS with cyclodextrins as 
solubilizing agents 
Preparation and characterization of cyclodextrin complexes of THC-HS by different 
techniques: 
 Phase solubility 
 NMR spectroscopy 
 UV spectroscopy 
 FT-IR spectroscopy 
 Molecular Modeling  
Chapter 4: Assessment of chemical and enzymatic stability of THC-HS:cyclodextrin 
complexes in solution-state 
Chemical stability and enzymatic hydrolysis studies in buccal homogenates were 
performed: 
 pH degradation profile  
 Enzymatic hydrolysis studies in buccal homogenates   
 In vitro buccal permeability of aqueous solutions of THC-HS:cyclodextrin complexes 
Chapter 5: Preparation of solid dispersions of THC-HS:cyclodextrins and study of 
their thermal stability and release characteristics  
 Accelerated stability testing of solid dispersions of THC-HS:cyclodextrins  
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 Dissolution release profile characterization of solid dispersions of THC-HS:cyclodextrin 
complexes 
 In vitro buccal permeability of solid dispersions of THC-HS:cyclodextrins 
Chapter 6: Formulation studies of hot-melt cast films of THC-HS-RAMEB solid dispersions  
 Effect of processing temperature on stability of THC-HS:RAMEB complex in 
transmucosal films 
 Content uniformity of hot-melt cast films containing THC-HS:RAMEB complex in 
transmucosal films 
 Effect of PEO-N80 on the stability of THC-HS:cyclodextrin solid dispersions in 
polymeric transmucosal matrix system  
 Effect of plasticizers/processing aids on the stability of THC-HS:cyclodextrin solid 
dispersions in polymeric transmucosal matrix system  
 Effect of various pH modulators to modulate the microenvironmental pH and stabilize the 
prodrug in polymeric films 
 Effect of  anti-oxidants and their combinations on stability of THC-HS incorporated into 
the matrix patch system  
Chapter 7:  Design of Experiments approach to identify critical formulation 
variables 
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Chapter 8: Preformulation studies of ∆9-Tetrahydrocannabinol aminophenyl butyrate 
(THC-APB)  
 To study the pH solubility and pH stability profile of THC-APB 
 To study the feasibility of incorporating THC-APB in hot-melt films 
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CHAPTER 3 
Preparation and characterization of inclusion complexes of a hemisuccinate ester 
prodrug of ∆9-tetrahydrocannabinol  
with modified beta-cyclodextrins 
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3.1. Introduction 
∆9-Tetrahydrocannabinol is the primary active ingredient of the plant Cannabis sativa 
(marijuana) and is responsible for the majority of the pharmacological effects.
163
  While THC in 
marijuana is mainly known for its abuse potential, it also exhibits therapeutic effects in the 
treatment of nausea and vomiting during cancer chemotherapy, in appetite stimulation, cachexia 
associated with AIDS, glaucoma, analgesia, and other indications.
164-168
 To date, the most 
promising clinical applications approved by the Food and Drug Administration (FDA) are for the 
control of nausea and vomiting associated with chemotherapy and for appetite stimulation of 
AIDS patients suffering from anorexia and wasting syndrome. It is significant to note that the 
only dosage form currently approved by FDA is an oral, soft gelatin capsule (e.g. Marinol
®
). In 
addition, orally administered THC has shown slow and variable absorption due to low oral 
solubility/permeability and first pass metabolism.
168
 The alternative routes of administration such 
as inhalation/smoking of THC have demonstrated more consistent and higher plasma drug levels; 
however, these methods are not desirable as they bear the potential of drug abuse. Moreover, the 
efficacy of smoked THC is largely dependent on the experience level of the subject with 
experienced smokers being able to self-titrate to achieve the desired symptomatic relief.  
Parenteral drug delivery of THC is besieged with the problems of being invasive and requiring 
professional assistance, and therefore in many cases precludes self medication.  In addition, this 
route is inherently subject to abuse. These limitations of the alternative routes of administration 
underline the need to explore various drug delivery strategies for oral administration of THC. 
The recent advances in drug delivery technologies make an oral administration an attractive 
approach to redevelop THC formulations without its earlier limitations.  The problems associated 
with low solubility/permeability and first-pass metabolism can be overcome with the help of 
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currently developing supersaturating drug delivery systems. A variety of formulation approaches 
under the consortium of supersaturating delivery systems for intestinal absorption are being 
applied to solubilize and maintain the supersaturation of water-insoluble drugs for a time period 
sufficient for absorption.
169
 They include solubilized formulations such as cosolvent systems, 
lipid-based formulations as well as high energy solids like amorphous, crystalline salt forms, co-
crystals and prodrugs. Our strategy towards developing THC oral formulations uses a two-
pronged approach  a) development of a new generation of hydrophilic prodrugs of THC (use of 
high energy solids), and  b) solubility enhancement and stabilization of prodrugs in oral 
formulations. The approach of synthesizing more hydrophilic prodrugs of the molecule has been 
successfully used in modifying the physico-chemical properties of the parent drug without 
changing the core structure of the compound.
170,171
 The prodrugs thus synthesized cleave the 
parent drug at appropriate pH and protect the parent moiety from any chemical modification 
before it reaches its desired target.  
Thus, a first generation prodrug of THC, the hemisuccinate ester of THC (THC-HS, Fig. 
3-1) was synthesized. It is a light-yellow, viscous liquid that is sticky at room temperature and 
hardens upon refrigeration, suggesting that the glass transition temperature is below 25°C, 
thereby necessitating its storage under freezing conditions for stability purposes. 
 
Figure 3-1: Structure of THC-HS 
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THC-HS has a molecular weight of 414.53 and logP of 3.33 (Moriguchi‘s method), is 
sparingly soluble in water, and mostly acidic with a pKa of 4.25 (ACD/Labs, Toronto, Ontario, 
Canada).
30,31
 Indeed the prodrug itself is not without problems; one of the main issues being its 
high hydrolytic potential.   
The other problems associated with transmucosal oral delivery of THC-HS are: a) high 
instability to heat and hydrolysis and prone to oxidation, b) the poor solubility of the prodrug 
(better than the parent drug) making its absorption, dissolution rate- limited, and c) since the 
prodrug is sticky and resinous in nature, handling issues are a major concern in formulation of 
the drug. Hence, suitable methods need to be employed to make it free-flowing. At this stage, a 
solubilization approach was adopted to enhance the solubility of THC-HS and maintain a higher 
concentration in the gastrointestinal tract (GIT) in order to enhance absorption.  Earlier, attempts 
have been made by Repka et al to enhance the solubility and stability of THC-HS using different 
polymers, solubilizers, anti-oxidants and pH modifiers.
30,31,172,173
 These solubilization methods 
were only moderately successful in increasing the solubility of THC-HS warranting a better 
solubilization strategy. One of the most commonly used technologies to enhance the solubility 
and, in turn, the absorption of water-insoluble drug molecules from the GIT is the use of 
cyclodextrin complexation of drugs.  
Cyclodextrins (CDs) are cyclic oligosaccharides composed of 6-8 dextrose units (α-, β- 
and γ CDs respectively) joined through 1-4 bonds. Because the interior of these molecules are 
relatively hydrophobic and the exterior relatively hydrophilic, they tend to form inclusion 
complexes of the type shown in the Fig 3-2.  
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Figure 3-2: Equilibrium binding of a drug with a CD to form a 1:1 inclusion complex 
α- and β-CDs are known to be parenterally unsafe due to severe nephrotoxicity caused by 
either CD uptake by the kidney tubule cells followed by disruption of intracellular function, or 
the extraction of lipid membrane components by the CD. Modification of the parent CDs to 
improve the safety, while maintaining the ability to form inclusion complexes with various 
substrates, has led to the synthesis of highly water-soluble random methylated beta-CD 
(RAMEB), 2-hydroxyprpoyl- beta-CD (HPBCD), sulfobutyl ether- beta-CD (SBECD), etc. 
These synthetically modified CDs have better solubility and excellent safety profiles compared 
to the parent CDs. They have been used in parenteral, oral, transdermal and ocular formulations. 
Synthetic CDs like RAMEB, HPBCD and SBECD are approved by regulatory agencies in the 
USA and Europe.
174-179
 
By the virtue of being able to form inclusion complexes with the drugs, CDs are known 
to enhance the solubility and protect the ester linkage of the compounds from hydrolysis. A vast 
amount of literature is published supporting the enhancement of bioavailability for oral 
formulations due to the inclusion complex formation with CDs.
34,36,180-185
 However, in very few 
cases the absorption was hindered due to CD binding to the free drug and thus reducing its free 
concentration.
184
 In the process of inclusion complexation, the drug and CD are in dynamic 
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equilibrium with each other leading to the inhibition of precipitation upon dilution up to a certain 
threshold. This phenomenon leads to the formation of supersaturated solutions of drug and CDs 
in the GIT with an enhanced absorption profile. In addition, the drugs can be lyophilized with the 
modified CDs to yield free-flowing powders. As a result, it was determined worthwhile to 
explore these advantages offered by CDs to develop an oral formulation for this ester prodrug of 
THC (THC-HS). The range of effects produced by CD complexation on absorption of water-
insoluble molecules is variable due to the chemical nature of the drugs, dose and drug: CD ratio. 
Hence it is difficult to predict a priori or create a generalized model of efficacy of CD with every 
drug molecule. Yet, it is important to understand the physical and chemical interactions of CDs 
with the individual drug molecule to predict the efficacy of the complexation process on that 
particular drug. As a first step towards the development of oral controlled formulations of THC-
HS, we are reporting the preformulation studies of CD inclusion complexes with THC-HS. The 
objective of this work is to determine the feasibility of inclusion complex formation of THC-HS 
with two beta-CD derivatives to enhance the solubility of THC-HS.  For this purpose, solid 
dispersions of THC-HS-beta -CD derivatives were prepared by different techniques 
(Coevaporation, adsorption and lyophilization) and characterized by proton NMR, Fourier 
transform Infrared spectroscopy (FT-IR), Job‘s plot and molecular modeling.  
3.2. Materials 
The following chemicals were used as received: randomly methylated beta-CD 
(RAMEB) and 2-hydroxyprpoyl- beta-CD (HPBCD) were purchased from Sigma Aldrich with a 
degree of substitution of 1.7 and 0.6, respectively. HPLC-grade water was freshly prepared in the 
laboratory (by Nanopure systems, Barnstead, Dubuque, IA). HPLC-grade acetonitrile and 
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methanol and were obtained from Fisher Scientific, Fair Lawn, NJ; THC-HS (in hexane) and 
THC (in absolute ethanol) were provided by ElSohly Laboratories Inc, Oxford, MS. 
3.3. Methods 
For preparation of the complexes, aqueous solutions of RAMEB/HPBCD and THC-HS 
were equilibrated for 24 h at 25°C under constant shaking at 100rpm. The samples containing 
THC-HS and RAMEB/HPBCD were lyophilized at -50°C in a lyophilizer (Labconco freeze dry 
systems / Freezone 2.5). The freeze-dried powders of the THC-HS: RAMEB/HPBCD complex 
were used for NMR and FT-IR studies.  
3.3.1 Phase solubility studies 
The phase solubility study was performed by employing a previously reported procedure 
by Higuchi.
186
 Briefly, THC-HS:RAMEB/THC-HS:HPBCD complexes in aqueous solutions 
were prepared by adding an excess amount of THC-HS to RAMEB/HPBCD solutions of 
different concentrations (10mM-200mM). The suspensions were equilibrated for 24 h at 25°C at 
100 rpm under constant shaking. After equilibration, undissolved THC-HS was removed from 
the suspensions by centrifugation. Intrinsic solubility (S0) of THC-HS in pure water was 
determined by following the same protocol, but without addition of CDs. All of the samples were 
prepared in triplicate. The concentration of THC-HS in the inclusion complexes was determined 
by HPLC assay. Stability constants for the formation of inclusion complexes between THC-HS 
and RAMEB were determined from the phase-solubility data using the equation (1): 
Ks = slope/S0 (1-slope)    (1) 
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3.3.2. NMR spectroscopy 
The 
1
HNMR spectra were recorded at 25°C on a Bruker 400 MHz spectrometer using a 5 
mm NMR probe. Since the aqueous solubility of THC-HS is extremely low, the spectra had to be 
recorded in deuterated water: methanol (1:1). For proton NMR, 128 scans were recorded with the 
following parameters: 32k data points, pulse width of 4.0µs and relaxation delay of 1s. Digital 
zero filling to 64K and a 0.5Hz exponential were applied before Fourier Transformation. 
1HNMR chemical shifts variations (Δδ) were calculated according to the equation (2)187,188:  
Δδ = δ (complex) – δ (free)    (2) 
3.3.3. Job’s plot 
The job‘s plot of THC-HS was determined from 1H NMR and UV data, according to the 
continuous variation method.
189
 The NMR experiment was carried out with solutions of THC-HS 
and RAMEB/HPBCD in deuterated water: methanol (1:1). The total molar concentrations of 
THC-HS and RAMEB/HPBCD were kept constant at 20mM, but their mole fractions were 
varied. The chemical shift in the proton signals due to the complex formation was plotted against 
the mole fraction of the two components. Solutions of the same composition, but in unbuffered 
water only, were used for UV-spectrophotometric determination of the stoichiometry. In this 
case, the shift of λmax of the UV spectrum of THC-HS was plotted against the mole fraction of 
the two components. Spectra were obtained with a Shimadzu UV-Vis spectrophotometer.  
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3.3.4. Fourier Transform Infrared Spectroscopy  
The FT-IR spectra were acquired for the lyophilized powders of THC-
HS:RAMEB/HPBCD complexes (1:1). FT-IR spectra were recorded using a universal attenuated 
total reflection sampling accessory with a Zinc Selenide crystal on a Perkin-Elmer Spectrum 100 
FT-IR spectrometer. The results were the means of 3 determinations. The physical mixtures of 
drug alone and RAMEB /HPBCD were used as blank. 
3.3.5. Molecular Modeling 
Molecular modeling studies were carried out using Maestro molecular modeling suite 
(Schrödinger Inc.). The three-dimensional structure of β-CD was obtained from the protein 
complex of alpha-amylase (pdb id:1jl8.pdb) available from the protein data bank. The CD was 
then extracted and dimethylated using Maestro molecular modeling suite (Schrödinger, LLC, 
New York, NY, 2005). Modified CD aka dimethyl-β-CD (DIMEB) was then energy minimized 
to remove the steric hindrance and clashes that can appear in the building process due to addition 
of two methyl groups. DIMEB was adopted as a substitution for RAMEB to facilitate modeling 
studies.
190
  A similar protocol was used to generate the three-dimensional structure of HPBCD. 
The structure of THC and THC-HS were sketched and energy minimized using Maestro. 
Molecular docking experiments were carried out using Glide (Glide, version 4.0, Schrödinger, 
LLC, New York, NY, 2005) module of Schrödinger molecular modeling suite. Glide searches 
for favorable interactions between small molecules (ligand, THC-HS in this case) and a receptor 
molecule (DIMEB/HPBCD in this case). The flexible docking procedure using Glide 
automatically generates conformations for each input ligand. Each conformer generated is then 
positioned into the cavity of DIMEB/HPBCD to find the preferred binding geometries. The most 
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likely conformation of the complex was the one with the lowest energy. The parent THC 
structure was also used in docking studies for comparison with THC-HS. The docked 
conformation of the THC and THC-HS were merged into the DIMEB and/or HPBCD. The 
resultant complexes were then minimized using OPLS2002 force field using Macromodel 
module of Maestro molecular modeling suite. The minimized energy of the complex represents 
E(complex). The binding energy (E) upon complexation between THC-HS and DIMEB/HPBCD 
calculated for the minimum energy structure is defined in Eq. (3)
191
: 
∆𝐸 = 𝐸 𝑐𝑜𝑚𝑝𝑙𝑒𝑥  − (𝐸𝑇𝐻𝐶−𝐻𝑆 + 𝐸𝐶𝐷)    (3) 
where, E(complex) represents minimized energy of the complex. ETHC-HS and ECD represent 
the energies of the guest (THC-HS) and host (CD) for the configuration extracted from the 
optimized complex geometry. The magnitude of the energy change would be a sign of the 
driving force towards complexation. The more negative the binding energy is the more 
thermodynamically favorable is the inclusion complex. 
3.4. Results and Discussion 
3.4.1. Phase Solubility studies 
The apparent solubility of THC-HS increases linearly with increasing concentrations of 
RAMEB as well as HPBCD. The aqueous solubility of THC-HS was increased one hundred-fold 
from an intrinsic aqueous solubility of 0.092mM to 9mM, in the presence of 0.18 mM RAMEB.  
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Figure 3-3: Phase solubility plot of THC-HS (RAMEB and HPBCD) 
The phase solubility plot of THC-HS with RAMEB and HPBCD is shown in Fig. 3-3.The 
slope of the phase solubility diagram is smaller than unity, over the entire concentration range 
studied, indicating an AL type diagram as seen in Fig. 3 with the formation of a complex with 1:1 
stoichiometry.   
Table 3-1: Solubility and association constants of THC-HS and THC (mM) in RAMEB and HPBCD 
Compound Solubility (mM) K (1:1) M
-1
 
 
RAMEB 
(150mM) 
HPBCD 
(150mM) 
RAMEB HPBCD 
THC-HS 8.088 ± 0.65 3.24 ± 0.89 562.48 ± 5.2 238.83 ± 4.3 
THC 5.63 ± 0.9 4.49 ± 1.2 
21137.44 ± 
15.6 
15589.88 ± 
23.0 
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The calculated association constant (K1:1) from Table I for the THC-HS–RAMEB 
complex is 562.48 M
-1
 indicating that THC-HS:RAMEB complexes (1:1 molar ratio) are 
moderately stable. Actually, lower values of K1:1 indicate a weak interaction between drug and 
CD, while higher values mean an incomplete drug release from the inclusion complex.  The 
association constant with HPBCD (238.83M
-1
) is lower than that obtained with RAMEB. The 
higher solubilization in the case of RAMEB is attributed to the presence of hydrophobic methyl 
groups which extend the hydrophobic cavity of the CD molecule. The values of the association 
constants of THC-HS indicate a moderately strong complex with RAMEB and a weak complex 
with HPBCD. The association constant for the parent THC molecule with RAMEB and HPBCD 
were determined to be 21,137.44 M
-1
 and 15,589.88 M
-1 
respectively. These values were in 
agreement with those reported by Manilla et al.
192
 The higher association constants of CDs with 
THC are indicative of a tighter binding with the CDs and thus lower free drug concentration. 
3.4.2. NMR spectroscopy 
NMR studies with RAMEB are not without difficulty because any collection of modified-
beta-CD molecules is a highly complex mixture of different isomeric forms of variously 
substituted beta-CD derivatives. Hence only several of the NMR-signals for THC-HS could be 
unambiguously identified as shown in Fig.3-4.  
The signals from RAMEB were inconclusive and could therefore not be interpreted with 
confidence. Therefore, the prediction of the orientation of THC-HS in the complex with 
RAMEB/HPBCD is a fair approximation using an array of different techniques to make definite 
conclusions. In 
1
H -NMR, significant changes in chemical shifts of protons of the free acid group 
of the hemisuccinate side chain of THC-HS as well as the protons of the phytyl side chain and 
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the aromatic ring of THC-HS were observed.  Especially the protons of the side chain were 
found to shift to the maximum extent followed by the carboxylic acid proton indicating that the 
hydrogen bonding and van der waals interactions are involved in the inclusion complex 
formation. 
 
Figure 3-4: Structure of THC-HS (Protons showing significant changes in chemical shifts shown in 
different colors) 
It was predicted that the molecule could be entering the CD cavity with its aliphatic side 
chain inserted into the cavity followed by the aromatic ring. The largest chemical shift in signals 
of H2, H4 H3‘, H5′ and H12 for THC-HS were observed while that of H7, H8 and H11 remained 
unaffected (Fig. 3-4). These data indicate an inclusion of ring A and the alkyl side chain of THC-
HS into the RAMEB cavity. This may be explained in that the alkyl side chain completely enters 
the CD cavity and protrudes from the opposite end, exposing H5′ to the solvent. Protons in the 
ring C were mostly unaffected indicating that the C ring might not be included in the 
hydrophobic cavity of RAMEB. This is also in good agreement with the observations of 
Hazekamp et al
188
 who reported non inclusion of ring C of THC in RAMEB. Aromatic protons at 
H2 and H4 undergo an expected upfield shift upon inclusion in the complex. The hemisuccinate 
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H12 proton exhibited a downfield shift possibly due to its interaction with the solvent.  The 
relatively small Δδ values observed for all signals indicate a relatively weak association. 
3.4.3. Job’s Plot 
Several techniques such as DSC, IR and UV-Vis spectroscopy can establish whether 
guest molecules form an inclusion complex with CDs, however they cannot provide information 
about the structural configuration of the complex.
193,194
 In contrast, NMR is a technique that 
provides the most useful evidence for the inclusion of a guest into the hydrophobic CD cavity in 
solution.  Two different techniques were used for preparation of a Job‘s plot in order to 
determine the stoichiometry of the inclusion complex. Thus, the ratio of RAMEB/HPBCD and 
THC-HS was varied, while the sum of their concentrations was kept constant, and a continuous 
variation plot was prepared. The chemical shift in the proton signals in NMR / shift of λmax due 
to the complex formation in UV spectroscopy were plotted against the mole fraction of the two 
components (Fig. 3-5 & Fig. 3-6).  
 
Figure 3-5:  Job‘s plot (NMR spectroscopy) 
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Figure 3-6:  Job‘s plot (UV spectroscopy) 
Using this method the value for Δδ reaches a maximum at the stoichiometric point. The 
results from UV as well as NMR spectroscopy yielded a 1:1 stoichiometry of THC-HS to 
RAMEB/HPBCD.  In a linear 1:1 stable complex, the plot usually has a triangular form with a 
maximum, while the formation of weak complexes results in curved plots indicating that the 
complex formed between THC-HS and RAMEB/HPBCD is not a strong one.  The values 
obtained of association constants also suggest the same.  
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3.4.4. Infrared Spectroscopy 
 
Figure 3-7: FT-IR spectra of Lyophilized complex of THC-HS &RAMEB (a), THC-HS (b), physical 
mixture of THC-HS &RAMEB (c) and RAMEB (d) 
THC-HS was characterized by bands around 1700-1500cm
-1
 and 1300-1100cm
-1
 (Fig. 3-
7). The FTIR spectra of CDs showed intense bands at 3600-3200 cm
-1
, corresponding to 
absorption by hydroxy groups. The bands that appeared at 3000-2800 cm
-1
 were assigned to 
stretching vibrations of the bonds in –CH and –CH2 groups. In THC-HS spectra, C=O stretching 
vibrations, (1758cm
-1
, 1713cm
-1
), -CH2 bending vibration (1424cm
-1
) were used to assess the 
interaction between RAMEB and the guest molecule (THC-HS) in the solid state. The spectra of 
the physical mixture as well as the lyophilized mixture did not show any new peaks indicating 
that no new chemical bonds were created in the formed complex. In the physical mixtures, the 
spectra were the exact superposition of those of the pure compounds, except that the intensities 
of the peaks had reduced to some extent (Fig. 3-7).  However, in the spectra of inclusion 
complexes, especially with RAMEB (Fig. 3-7), the  bands arising from all of the major 
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interactions like C=O stretching vibrations, (1758cm
-1
, 1713cm
-1
) and -CH2 bending vibration 
(1424cm
-1
) have decreased in intensity and moved toward the left. This is likely due to the 
restrictions in the vibrations from hydrogen bonding during CD complexation. The bands located 
at 1758cm
-1
 and 1713 cm
-1
 are correlated to the stretching vibrations of the carbonyl group of the 
ester and the free carboxylic acid, respectively. In the lyophilized complex of THC-HS and 
RAMEB, the band from the free carboxylic acid at 1713 cm
-1
 (shifted to 1735 cm
-1 
in lyophilized 
complex) has broadened and decreased in intensity due to the potential hydrogen bonding. The 
band from the ester carbonyl group did not show any shift in the wavelength upon complexation 
but was visible at a very low intensity indicating that the hydrogen bonding interactions with 
RAMEB are primarily occurring at the free carboxylic acid end of the guest molecule (THC-
HS). Another important interaction observed at 1424cm
-1
 is –CH2 bending vibrations. This band 
is also minimized in intensity as it relates to the hydrocarbon chain of THC-HS. As compared to 
RAMEB, the HPBCD inclusion complex of THC-HS did not show any significant interaction 
and the differences in the IR spectrum of the physical mixture and lyophilized complexes were 
too subtle to be identified. It is likely that the molecule enters the CD molecule with its 
hydrocarbon tail inserted into its hydrophobic cavity first with the hemisuccinate ester side chain 
in close proximity to the rim hydroxyl groups of RAMEB. These results support the assumption 
that the inclusion complex was formed when the lyophilization was used in contrast to the 
physical mixture of THC-HS and RAMEB/HPBCD (Fig 3-7). FT-IR spectrum for THC-HS 
HPBCD complex could not be clearly deciphered due to the low binding affinity of THC-HS for 
HPBCD (Data not shown). 
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3.4.5. Molecular Modeling 
The docking studies indicated that the aromatic ring and the appended hydrophobic 
phytyl chain of the THS-HS molecule are oriented inside the cavity of DIMEB (Fig. 3-8).  
 
Figure 3-8. Binding pose of THC-HS within DIMEB cavity during formation of THC-HS:RAMEB 
complex, as predicted by Glide docking program. 
From this figure, the tricyclic ring of THC-HS shows van der waals interactions with the 
hydrophobic cavity of DIMEB. It is quite significant to note that no fixed constraints were 
imposed during the docking calculations and the docking results corroborated with the data 
obtained from NMR and FT-IR spectroscopy. The terminal carboxylic acid functional group of 
the hemisuccinate ester side chain is involved in hydrogen bonding interactions with one of the 
hydroxy groups on the surface of DIMEB. The NMR results demonstrated changes in the 
chemical shift values of a few protons, including the aromatic and the phytyl chain protons. As 
can be further seen from Fig. 3-8, the protons shown in yellow are submerged inside the DIMEB 
cavity. Similarly, IR studies showed shifting of a carboxylic acid stretch due to hydrogen 
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bonding interactions with one of the hydroxy groups of CD. The docking studies revealed that 
the carboxyl group of the hemisuccinate side chain lies within hydrogen bonding distance from 
the hydroxy of DIMEB (2.7Å).  
 
Figure 3-9: Binding pose of THC-HS within HPBCD cavity during formation of THC-HS:HPBCD 
complex, as predicted by Glide docking program 
The docking studies of THC-HS with HPBCD demonstrated a lower binding affinity of 
the ligand for HPBCD (Fig. 3-9).  
Table 3-2: Binding energies and docking scores of the inclusion complexes of THC-HS and THC 
Complex ID 
Binding 
Energy 
Van der Waal 
Energy 
Docking 
score 
THC-HS - DIMEB -182.9 -66.69 -5.42 
THC-HS - 
HPBCD 
-125.23 40.43 -2.96 
THC-DIMEB -137.74 -42.47 -5.65 
THC- HPBCD -125.07 40.43 -3.33 
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In Table 3-2, the binding energies, along with the van der Waals energies and the docking 
scores of the various inclusion complexes of THC-HS and THC with DIMEB and HPBCD are 
provided. THC and THC-HS showed similar docking scores (-5.42 and -5.67). Hence, the 
binding energy calculations were performed to understand the stability of the two complexes.  It 
is evident that the THC-HS showed better binding and thus complexation (∆𝐸 = -182.9 kJ/mol) 
with DIMEB compared to the parent molecule THC (∆𝐸 = -137.73 kJ/mol). THC-HS: DIMEB 
complex shows the lower binding energy and docking score compared to the THC-HS: HPBCD 
complex, suggesting that the later is energetically less favored. This data is also supported by 
strong van der Waals interactions reflecting the snug fit of THC-HS obtained while 
complexation with DIMEB ( -66.69 kJ/mol) as compared to HPBCD (-40.43 kJ/mol) When 
compared with THC, the binding energy of the THC: DIMEB complex (BE = -137.74 kJ/mol) is 
significantly higher than that of the THC-HS: DIMEB complex (BE = -182.9 kJ/mol).
195
 Higher 
the binding energy, lower the binding affinity and hence the lower solubility too. THC-HS thus 
showed higher solubility than THC in DIMEB. The molecular modeling results correlated very 
well with the phase solubility and NMR spectroscopic data in that RAMEB was able to better 
solubilize THC-HS as compared to HPBCD. The best possible mode of binding of THC-HS with 
DIMEB is shown in Fig. 3-10.  
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Figure 3-10: Orientation of THC-HS molecule in DIMEB cavity, the polar portion of THC-HS oriented 
outside the cavity,  as predicted by Glide docking program 
From this figure, it is very clear that the alkyl chain is embedded in the hydrophobic 
cavity of DIMEB whereas the hemisuccinate ester side chain forms hydrogen bonding 
interactions with one of the surface hydroxyl groups of the DIMEB molecule. 
3.5. Conclusion 
Inclusion complexes of THC-HS with various modified CDs were prepared by 
lyophilization and characterized using several techniques such as phase solubility, NMR, FT-IR 
spectroscopy and molecular modeling. The aqueous solubility of THC-HS was increased by 
almost 100-fold due to the inclusion complex formation with RAMEB. HPBCD was unable to 
form a stable complex with THC-HS and subsequently enhance its solubility in aqueous 
medium.  The results obtained from phase solubility and Job‘s plot suggests the formation of a 
1:1 inclusion complex of THC-HS and RAMEB. NMR and FT-IR spectroscopy were useful in 
characterization of the structure of the inclusion complex formed. Higher association constants 
were obtained and in turn, better solubilization of THC-HS was achieved by RAMEB as 
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compared to HPBCD. Our experimental data was well-supported by molecular modeling studies 
suggesting energetically favorable inclusion complex formation of the THC-HS: RAMEB 
complex as compared to the THC-HS: HPBCD complex. The complex formation of THC-HS 
with RAMEB and HPBCD predicted by molecular docking studies corroborated well with the 
results of  NMR and FT-IR spectroscopy. CDs have aided in solubilization of THC-HS in vitro 
and the solid dispersions of THC-HS and RAMEB will be further incorporated into solid dosage 
forms for development of stable oral controlled release THC formulations.  
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CHAPTER 4 
Chemical stability and Enzymatic hydrolysis of complexes of a 
hemisuccinate ester of ∆
9
-THC in presence of modified cyclodextrins 
  
71 
 
4.1. Introduction 
Cyclodextrins (CDs) are water-soluble naturally occurring cyclic glucose oligomers 
which have the ability to include selectively a range of guest species in their hydrophobic cavity. 
The formation of an inclusion complex potentially alters the physical and chemical properties of 
the guest molecule. The binding forces associated with the CD-guest inclusion formation are 
attributed to a number of factors such as hydrophobic forces, hydrogen bonding, size of the 
cavity, shape of the guest molecule and electrostatic interactions.
196,197
Several previously 
published reports have documented the use of cyclodextrins to improve solubility, stability and 
bioavailability of drugs. Recently, we published solubilization studies of a hemisuccinate ester of 
∆9-Tetrahydrocannabinol (THC-HS) with modified cyclodextrins.197 (∆9-Tetrahydrocannabinol 
(THC) is the primary active ingredient of the plant Cannabis sativa (marijuana) and is 
responsible for the majority of the pharmacological effects.   While THC in marijuana is mainly 
known for its abuse potential, it also exhibits therapeutic effects in the treatment of nausea and 
vomiting during cancer chemotherapy, in appetite stimulation, cachexia associated with AIDS, 
glaucoma, analgesia, and other indications.
163
 To date, the most promising clinical applications 
approved by the Food and Drug Administration (FDA) are for the control of nausea and 
vomiting associated with chemotherapy and for appetite stimulation of AIDS patients suffering 
from anorexia and wasting syndrome. Orally administered THC from Marinol
®
 soft gel capsules 
has shown slow and variable absorption due to low oral solubility/permeability and first pass 
metabolism. 
The approach of synthesizing more hydrophilic prodrugs of the molecule has been 
successfully used in modifying the physico-chemical properties of the parent drug without 
changing the core structure of the compound.  Such reversible derivatization of the parent 
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molecule helps in improving its pharmacokinetic properties and drug delivery characteristics. 
Hence we have designed hydrophilic prodrugs of THC such as THC-HS to overcome the 
pharmacokinetic limitations of the parent molecules of the parent molecule, THC.  
The purpose of this study was to investigate the effect of cyclodextrins viz.; RAMEB and 
HPBCD on chemical and enzymatic stability and in vitro buccal permeation of THC-HS. This 
strategy would allow an increase in aqueous solubility without a change in the molecular 
structure and the intrinsic ability of the lipophilic esters to partition into biological membranes. 
Cyclodextrins are cyclic oligosaccharides with a hydrophilic outer surface and a hydrophobic 
central cavity. The hydrophilic exterior renders the cyclodextrin water-soluble and the 
hydrophobic interior provides a microenvironment for relatively non polar drugs. In aqueous 
solutions, cyclodextrins can form inclusion complexes with lipophilic drugs by entrapping either 
the entire drug molecule or a non polar part of it inside the hydrophobic cavity.
 
Such 
encapsulation may protect the prodrug against potential degradation by buccal membrane–bound 
and salivary esterases.
38
   
4.2 Materials 
Monobasic potassium phosphate, monobasic sodium phosphate, dibasic sodium 
phosphate and dibasic potassium phosphate were purchased from Spectrum Chemical, Inc., 
(Gardena, CA). Lithium chloride, hydrochloric acid (HCl), sodium hydroxide (NaOH), 
potassium hydroxide, sodium chloride, potassium sulfate, methanol and acetonitrile (both HPLC 
grade) were obtained from Fischer Chemicals (Fair Lawn, NJ). HPLC grade water was freshly 
prepared in the laboratory (by Nanopure system, Barnstead, Dubuque, IA) 
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4.3. Methods 
4.3.1. Chemical Stability Studies  
Stability of THC-HS at 25°C in three different pHs (3, 5 and 7.4-phosphate buffer), in the 
absence and presence of RAMEB/HPBCD (1% w/v) was determined. A prodrug stock solution 
(100 μL) in ethanol was subsequently added to the 1 ml of buffer solutions to yield a 
concentration of 10 µg/ml. The vials were placed in a constant shaker bath set at 25°C and 60 
rpm. Samples (100 μL) were collected at appropriate time intervals for up to 48 hours and stored 
at –80°C until further analysis. Linear regression of the log concentration versus time profiles 
yielded the pseudo first order rate constants of degradation. Degradation studies were also 
carried out using 1% RAMEB in pH 7.4 phosphate buffer saline, to study the effect of 
cyclodextrin on chemical stability of the prodrugs.  
4.3.2. Enzymatic Hydrolysis Studies  
Initially, protein estimation of buccal tissue homogenates was performed using Bradford 
reagent. Hydrolysis studies were carried out in the presence and absence of RAMEB/HPBCD 
(1% w/v) to determine if cyclodextrin complexation can increase the stability of THC-HS against 
enzymatic degradation by membrane-bound enzymes of the buccal mucosa. Ethanolic stock 
solutions of THC-HS:RAMEB/HPBCD were added to porcine buccal tissue homogenates in pH 
7.4 buffer at 25°C. Samples were withdrawn every 15 minutes for the first hour and every 30 
minutes for the next 2 hours, and the samples were subsequently stored at –80°C until further 
analysis was performed. Studies were performed in triplicate. The solutions were analyzed for 
THC-HS content.  
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4.3.3. In Vitro Permeability Studies  
Buccal membrane permeation studies were carried out using stripped porcine buccal 
mucosa. The porcine buccal mucosa was prepared by heat-stripping a piece of porcine jaw in 
water at 60°C according to the standard procedure. Immediately following excision, the mucosa 
was washed with ice-cold pH 7.4 buffer and mounted on side-by-side diffusion chambers with 
the epithelial side facing the donor compartment. The integrity of buccal mucosa was determined 
by electrical resistance apparatus. The temperature was maintained at 32°C. The donor 
compartment consisted of (a) aqueous solutions of THC-HS in presence of 0.1% SLS and 0.5% 
Cremophor RH 40 and (b) aqueous solutions of THC-HS in presence of 1%w/v RAMEB. The 
receiver compartment consisted same solutions as that of the donor compartment except THC-
HS. The donor and receiver compartments were stirred continuously with magnetic stir bars. The 
total duration of the transport was 8 hours and samples (600µl) were withdrawn from the 
receiver compartments for 30 minutes in the first hour and every hour in the next 7 hours. The 
samples were immediately replaced with an equal volume of receiver solution to ensure sink 
conditions. The samples were analyzed for THC-HS as well as regenerated THC by HPLC. All 
the experiments were conducted in triplicates.  
4.4. Results and Discussion 
4.4.1. Chemical stability studies 
One of the most common pharmaceutical applications of cyclodextrins is to enhance drug 
stability in aqueous solutions. Inclusion complex formation may be regarded as an encapsulation 
of the prodrug molecule or at least a labile ester segment of the molecule. Entrapment, partial or 
total can protect the prodrug against attack by various reactive species. This ability to form 
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inclusion complexes has been exploited to alter the chemical and physical properties of guest 
(drug) molecules, to improve water solubility, prolong in vivo stability, reduce toxicity and 
irritancy, and improve bioavailability.
38
 
Release of the guest molecule is governed by dissociation, and therefore selective 
chemical modifications can be employed to control equilibrium thermodynamics, and thus 
release rate.  
Table.4-1. lists the degradation rate constants of the complexed as well as free prodrug at 
37ºC in pH 3, 5, 7.4 phosphate buffer. There was a significant reduction in chemical hydrolysis 
of complexed prodrug as compared to free prodrug. RAMEB afforded better stability profile and 
lower degradation rate constants (fig.4-1 & Table 4-1) as compared to HPBCD at all the pHs 
tested. The effect was more pronounced at pH 5 where the prodrug has better stability profile due 
to its acidic nature. Complexation with RAMEB and HPBCD increased the half-life of THC-HS 
by approximately 12 fold and 8 fold respectively.  The higher stability is achieved with THC-HS 
having higher complexation constant with RAMEB as compared to HPBCD. 
THC-HS exhibits maximum stability between pH 3.0 and 5.0 and lower stability at pH 
7.4. The half life of THC-HS in RAMEB solutions increased to 55 hours and 17.5 hours at pH 3 
and 7.4 respectively as compared to 9 hours and 1.5 hours at same pHs for the uncomplexed 
prodrug.  It was shown earlier that THC-HS exhibited maximal stability at pH 3-4.5. However,, 
decreasing the pH of the dosage form to drastic levels like pH 3 may lead to enhancement in 
buccal irritation. Hence moderately enhanced stability of the complexed prodrug between pHs 5 
and 7.4 will definitely prove beneficial in formulation of transmucosal films with sufficient 
patient compliance.  
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Increased stability of the prodrugs in aqueous solutions of RAMEB/HPBCD solutions 
indicated that the ester moiety is at least partially enclosed in the cyclodextrin cavity.  It can be 
estimated that the ester linkage might be protected by either insertion in to the hydrophobic 
cavity of RAMEB/HPBCD or by forming hydrogen bonds with its rim hydroxyl groups. 
59
 
 
Figure 4-1: Chemical stability of THC-HS in presence of RAMEB & HPBCD 
 
Table 4-1: Chemical stability of THC-HS in presence of Cyclodextrins 
Compound pH 
 3.0 5.0 7.4 
THC-HS 0.076±0.013 0.246±0.04 0.462±0.043 
THC-HS:RAMEB 0.0124±0.0489 0.0158±0.0125 0.0395±0.0047 
THC-HS:HPBCD 0.0242±0.0125 0.0165±0.0035 0.0564±0.026 
 T 1/2 (hrs) 
THC-HS 9.118±0.013 2.805±0.04 1.5±0.043 
THC-HS:RAMEB 55.887±0.0489 43.860±0.0125 17.5443±0.0047 
THC-HS:HPBCD 28.636±0.0489 43.3125±0.0035 12.2873±0.026 
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4.4.2. Enzymatic hydrolysis  
In this study, in order to improve the stability and bioavailability of prodrug THC-HS, we 
investigated the effect of RAMEB and HPBCD on the enzymatic hydrolysis of THC-HS. In 
buccal homogenate studies, at a protein concentration of 0.5 mg/ml, enzyme mediated hydrolysis 
of THC-HS was decreased 3-folds in the presence of RAMEB in pH 7.4 phosphate buffer. The 
degradation rate constant was 0.0079 min
-1
 for THC-HS:RAMEB complex compared to a 
degradation rate constant of 0.023min
-1
 for THC-HS alone (fig.4-2 & Table 4-2). THC-
HS:HPBCD complex demonstrated a lower stability towards enzymatic hydrolysis with a 
degradation rate constant of 0.0114 min
-1
. It is apparent from the complex t1/2 values that 
RAMEB produced the least labile complex. The alkaline hydrolysis of THC-HS was 
considerably slower in presence of RAMEB and HPBCD. The degree of stabilization by CD 
complexation depends on both the hydrolysis rate of free THC-HS within the solution and within 
the complex. THC-HS had a much higher complexation constant with RAMEB than HPBCD 
which increased the fraction of complexed prodrug in the solution, thereby resulting in greater 
stabilization with RAMEB than HPBCD. A stronger association was observed for RAMEB than 
for HPBCD.  RAMEB which has secondary hydroxyls of each glucopyranose unit, and primary 
hydroxyls, methylated, was more efficient in the improvement of stability of nonpolar part of 
THC-HS. The methyl groups confer hydrophobicity close to the extremity of the hydrophobic 
cavity of the cyclodextrin and greater flexibility to its structure.  This yields a higher association 
constant. In case of HPBCD, the bulky hydroxypropyl groups on primary hydroxyls cause a 
steric hindrance and, consequently, a lesser association constant and a lesser stabilization effect 
on THC-HS. The buccal mucosa has been known to contain a high activity of various esterases 
and peptidases which may limit the absorption of enzymatic labile drugs such as prodrugs 
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following buccal or sublingual administration.
198
 Another absorption-limiting factor for such 
compounds may be degradation by enzymes in the saliva. Human saliva has been shown to 
contain a variety of esterases, mainly carboxylesterases and therefore, saliva-catalyzed 
degradation of ester prodrugs or drugs containing susceptible ester prodrugs may preclude an 
efficient buccal bioavailability.
131
 The catalytic effect of buccal as well as salivary esterases on 
the hydrolysis of THC-HS is evident by comparing the half-life of complexed prodrug in buccal 
homogenates with that in a pH 7.4 phosphate buffer at 37ºC. 
 
Figure 4-2: Enzymatic hydrolysis of THC-HS in presence of RAMEB & HPBCD 
 
Figure 4-3: First-order kinetic plots for the hydrolysis of THC-HS in buccal homogenates 
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Table 4-2: Enzymatic hydrolysis of THC-HS in presence of cyclodextrins 
Compound Degradation rate constant k 
(min
-1
) 
THC-HS 0.023±0.013 
THC-HS:RAMEB 0.0079±0.0489 
THC-HS:HPBCD 0.0114±0.0125 
 t 
1/2
 (min
-1
) 
THC-HS 30.13 ±0.013 
THC-HS:RAMEB 87.72 ±0.0489 
THC-HS:HPBCD 60.78±0.0125 
 
The half–life of complexed prodrug THC-HS with RAMEB has been reduced to 
approximately 88 minutes as compared to 17.5 hours in pH 7.4 phosphate buffer solution 
(Tale.4-2). However the complexed prodrug still exhibits a much better enzymatic stability as 
compared to free prodrug which is evident from its half-lives given in Table. 4-2. The results of 
the chemical and enzymatic degradation profile indicated that the complexed prodrug hydrolyzed 
at a much slower rate compared to the uncomplexed or free prodrug.  
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4.4.3. In vitro permeability studies 
 
Figure 4-4: In vitro permeability studies of THC-HS in presence of cyclodextrins 
Buccal mucosa is a potential site for drug absorption in alternative to oral drug delivery. 
Active molecules administered through the buccal mucosa pass directly into the systemic 
circulation, thereby minimizing the first hepatic pass and adverse gastro-intestinal effect. 
However, lower permeability of the buccal mucosa to large molecules can be problematic in 
order to achieve therapeutic levels of such molecules. Buccal permeation can be increased by 
using various penetration enhancers.
199
 Recently, cyclodextrins have been classified as a new 
class of penetration enhancers. It is generally recognized that cyclodextrins act as true carriers by 
keeping the hydrophobic drug molecules in solution and deliver them to the surface of the 
biological membrane, where they partition into the membrane.
200
 Cyclodextrins can enhance 
drug permeation by increasing drug availability and stability at the surface of the biological 
barriers. However, derivative cyclodextrins, especially methylated cyclodextrins, act as 
absorption enhancers by different pathways. These hydrophobic cyclodextrins act as absorption 
enhancers, probably, by transiently changing membrane permeability, overcoming the aqueous 
diffusion barrier and opening tight junctions. 
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Table 4-3: Comparative profiling of permeability parameters Indicated values are means  
(±SD, n = 3–4) 
Systems Papp (cm/s) Ratio
a
 Flux (µg/cm
2
.h) 
THC-HS 2.00E-08 1 0.07 
THC-HS_Surfactants 
(0.1%SLS + 0.5%Cremophor RH 40) 
2.25E-07 11.23 0.815 
THC-HS_RAMEB 1.27E-06 63.33 3.639 
THC-HS_HPBCD 6.70E-07 33.5 1.930 
a 
Enhancement ratio = Papp (sample)/Papp (control) 
In vitro permeation experiments demonstrated almost 63-fold increase in the permeability 
of THC-HS across excised buccal mucosa, in the presence of RAMEB (1.27 x 10
-6 
cm.sec
-1
 
compared to the permeation of THC-HS in the presence of Cremophor RH 40 and sodium lauryl 
sulphate (2.25x 10
-7
 cm.sec
-1
). Moreover, permeation lag time of THC-HS decreased to 2 h, from 
6-7 h, in the presence of RAMEB (fig.4-4, & Table 4-3.). Integrity of buccal mucosa was 
maintained throughout the experiment.  
Cyclodextrins enhance the permeation of the drug by carrying the drug through the 
aqueous barrier towards the surface of the membrane, where the drug passes from the complex 
into the membrane. Addition of RAMEB to the aqueous solution of THC-HS increased the flux 
by increasing the solubility of THC-HS, thus improving the diffusible form of the drug species at 
the buccal membrane interface. Though the complex did not penetrate the membrane, the drug in 
the complex was in rapid dynamic equilibrium with the ―free‖ drug, thus continuously supplying 
the drug molecules to the membrane surface in a diffusible form. The stability constant value for 
the THC-HS:RAMEB complex was found to be 562.48 M
−1
, indicating a moderately labile 
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association of THC-HS and RAMEB, which was desirable because only the free drug was in the 
diffusible form. The stability constant of the complex affected the drug diffusivity. The solubility 
and stability constant of THC-HS with HPBCD was low and its hydrolysis constant high 
indicating a less stable and soluble complex than that of RAMEB. Hence lower amounts of 
THC-HS permeated through the buccal mucosa in presence of HPBCD as compared to RAMEB.  
4.5. Conclusion 
Cyclodextrins were successful in enhancing the stability of THC-HS by virtue of forming 
of inclusion complex that serves in protection of hydrolysis of ester linkage of THC-HS. 
Modified cyclodextrins, especially RAMEB were able to increase the flux and decrease the 
lagtime associated with the permeation of THC-HS through the porcine buccal mucosa. 
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CHAPTER 5 
Thermal stability and release studies of lyophilized solid dispersions of a 
hemisuccinate ester of THC with modified cyclodextrins 
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5.1. Introduction 
Over the years, ∆9-Tetrahydrocannabinol (THC) obtained from Cannabis sativa has 
gained significant importance due to its use as an antiemetic in the treatment of nausea and 
vomiting in cancer chemotherapy. Marinol
® 
soft gel capsule and two of its generic versions are 
the only USFDA approved formulations available in the market for the treatment of 
chemotherapy related nausea and vomiting. Since THC from Marinol
®
 capsule is known to have 
variable absorption due to its high first pass metabolism, there is a need to develop formulations 
of THC for alternatives routes.  The transmucosal films of THC applied to buccal mucosa would 
enhance the bioavailability of THC by avoidance of first pass metabolism encountered through 
oral absorption. THC is known to be a very highly lipophilic and unstable molecule therefore 
hydrophilic prodrug of THC viz, ∆9-Tetrahydrocannabinol hemisuccinate (THC-HS) was 
synthesized to improve the physicochemical and pharmacokinetic properties of the parent 
molecule, THC. It was also thought that preparation of solid dispersions of THC-HS with 
cyclodextrins would have two-fold benefits in improving solubility as well as stability of the 
prodrug in cyclodextrin solution. Solid dispersions consist of a carrier in which a compound is 
dispersed as small particles. When the compound is molecularly dispersed, the term solid 
solutions or amorphous glass solutions is used.
201,202
 Solid dispersions are also used to accelerate 
dissolution of lipophilic compounds in the aqueous environment of the gastro-intestinal tract and 
thereby improving their oral bioavailability. 
202-204
 
Cyclodextrins (CDs) are versatile pharmaceutical excipients which are frequently used to 
improve the physicochemical and biopharmaceutical properties of drugs (e.g., solubility, 
stability, and bioavailability.
205,206
  CDs have the ability to include selectively a range of guest 
species in their hydrophobic cavity by virtue of forming inclusion complexes by encapsulating a 
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part of or whole molecular entity in its hydrophobic cavity. This molecular encapsulation 
increases the solubility
207
 (Manolikar & Sawant, 2003), chemical stability 
208
and absorption of 
the drug. Several previously published reports have documented the use of cyclodextrins to 
improve solubility, stability and bioavailability of drugs.  
Typically, different types of methods have been used for the preparation of inclusion 
complexes of drug with CDs. Some of these methods are grinding, slurry complexation, solvent 
evaporation and coprecipitation. All these method require excessive pharmaceutically 
unacceptable organic solvents and residual solvents need to be removed. Coprecipitation needs 
excessive CD and high temperature, and this is not suitable to heat unstable drugs like THC-HS. 
All these methods are difficult for industrial scaling up. Lyophilization, on the other hand is an 
industrially applicable method especially for heat labile drugs and biopharmaceutical 
compounds. It produces solid amorphous dispersions with good handling properties. Recently, 
we published solubilization studies of a hemisuccinate ester of ∆9-Tetrahydrocannabinol (THC-
HS) with modified cyclodextrins. 
197
The purpose of this study is to determine the optimum 
concentration of RAMEB and HPBCD required for dissolution enhancement and establish the 
most suitable method for preparing the solid dispersions. The aim of this study was to develop a 
chemically and physically stable dry powder containing THC-HS with improved solubilization. 
The stability of lyophilized solid dispersions of THC-HS with RAMEB and HPBCD was 
determined at different stability protocols to assess the effect of RAMEB and HPBCD on the 
content of THC-HS in lyophilized solid dispersions. In vitro permeation of THC-HS from the 
lyophilized solid dispersions of cyclodextrins across the porcine buccal mucosa was also studied 
to correlate the enhancement in solubility of THC-HS to its increased flux across the biological 
membrane. 
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5.2. Methods 
5.2.1. Preparation of inclusion complexes in solid state 
Solid dispersions were prepared with different molar ratios (1:1, 1:2, 1:5) of THC-HS and 
RAMEB /HPBCD using three distinct methods: physical mixture, coevaporation and 
lyophilization. Physical mixtures were prepared by adsorbing solution of THC-HS in hexane 
over the bed of RAMEB/HPBCD.  The mixture is air-dried and ground to a fine powder in a 
mortar.  Lyophilized mixtures were prepared by addition of known amount of THC-HS and 
RAMEB/HPBCD to water and freeze-drying the mixture at -50°C in a lyophilizer. Coevaporated 
samples were prepared by evaporating the aqueous dispersions of THC-HS and RAMEB under 
vacuum.  
5.2.2. Dissolution studies of solid dispersions of THC-HS:cyclodextrin complexes 
Dissolution studies of the solid dispersions were performed utilizing a Hanson SR8-Plus 
dissolution test system USP 31 apparatus 1 basket method. The dissolution medium consisted of 
500 ml of 0.5% SLS. The media were previously filtered, degassed and maintained at 37 ±0.5°C. 
The stirring speed was set at 50 rpm and the temperature was maintained at 37 ±0.5°C.  Aliquots 
from samples containing 10 mg of THC-HS or its equivalent in physical mixture or inclusion 
complex form, prepared by coevaporation, adsorption and lyophilization were withdrawn each 
15 min for a period of 60 min and analyzed by HPLC. Three replicates have been made for each 
experiment.  
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5.2.3. Accelerated stability testing of lyophilized THC-HS:RAMEB solid dispersions 
The inclusion complexes of THC-HS:RAMEB was prepared by lyophilization of THC-
HS and RAMEB (1:2 and 1:10 ratios). Stability of these solid dispersions was assessed at 4°C, 
25°C and 40°C in open and closed vials over a period of 1 month.  
5.2.4. In Vitro Permeability Studies of lyophilized THC-HS:RAMEB solid 
dispersions 
Buccal membrane permeation studies were carried out using stripped porcine buccal 
mucosa. The porcine buccal mucosa was prepared by heat-stripping a piece of porcine jaw in 
water at 60°C according to the standard procedure. Immediately following excision, the mucosa 
was washed with ice-cold pH 7.4 buffer and mounted on side-by-side diffusion chambers with 
the epithelial side facing the donor compartment. The integrity of buccal mucosa was determined 
by electrical resistance apparatus. The temperature was maintained at 32°C. The donor 
compartment consisted of aqueous solutions of THC-HS:RAMEB complex (1:2 & 1:10). The 
receiver compartment consisted of 7.4 buffer containing RAMEB (1%w/v). The donor and 
receiver compartments were stirred continuously with magnetic stir bars. The total duration of 
the transport was 8 hours and samples (600µl) were withdrawn from the receiver compartments 
for 30 minutes in the first hour and every hour in the next 7 hours. The samples were 
immediately replaced with an equal volume of receiver solution to ensure sink conditions. The 
samples were analyzed for intact THC-HS as well as regenerated THC by HPLC. All the 
experiments were conducted in triplicates.  
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5.3. Results and Discussion 
5.3.1. Dissolution studies of solid dispersions of THC-HS:cyclodextrin complexes 
It is interesting to note that the physical mixture of THC-HS with RAMEB and HPBCD 
does not contribute significantly to an improvement of drug dissolution rate. The possible 
explanation for this behavior is the non-formation of inclusion complex between the prodrug and 
the cyclodextrins. The coevaporated samples showed an enhanced dissolution rate which was 
much better than that obtained by physical mixtures of THC-HS and cyclodextrins. But the 
coevaporated samples suffered from handling difficulties along with the loss of drug due to the 
formation of sticky mass instead of free-flowing powders. The release of the THC-HS from 
lyophilized solid dispersions with RAMEB and HPBCD was enhanced as compared to the 
physical mixtures as well as co-evaporated samples. At 90 minutes, 90% of THC-HS was 
released from the 1:1 lyophilized RAMEB complex as against 67% from the adsorbed physical 
mixtures and 50% from the co-evaporated mixtures (fig. 5-1).  At the end of 30 minutes, the 
percent drug dissolved from the control (THC-HS) was only 14% while percent drug dissolved 
from 1:5 lyophilized dispersions of THC-HS:RAMEB and THC-HS:HPBCD was 90.3% and 
72.0%, respectively. An increase of THC-HS:RAMEB molar ratio from 1:1 to 1:5 increased the 
dissolution of THC-HS from 66% to 90.3% at the end of 30 minutes (fig. 5-2). At the highest 
concentration i.e. 1:5 ratio of THC-HS:HPBCD (fig 5-4), at the end of 30 minutes only 72% 
drug was released as against 90.36 % from RAMEB lyophilized solid dispersions. RAMEB was 
significantly more effective than HPBCD in improving the dissolution rate of THC-HS from the 
lyophilized as well as co-evaporated solid dispersions. The physical mixture as well as 
coevaoprated sample were found to be an inappropriate method of producing solid dispersions of 
THC-HS:RAMEB/HPBCD as the drug produced sticky, glassy dispersions which were difficult 
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to handle (fig. 5-3). Incomplete release was found from the physical mixtures of THC-
HS:RAMEB and THC-HS:HPBCD even after three hours of dissolution testing.  
 
 
Figure 5-1: Dissolution profiles of THC-HS:RAMEB lyophilized solid dispersions  
(different methods) 
 
Figure 5-2: Dissolution profiles of THC-HS:RAMEB lyophilized solid dispersions  
in different ratios 
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Figure 5-3: Dissolution profiles of THC-HS:HPBCD lyophilized solid dispersions 
 in different methods 
 
Figure 5-4: Dissolution profiles of THC-HS:HPBCD lyophilized solid dispersions  
in different ratios 
 
Figure 5-5: Comparison of dissolution profiles of THC-HS:RAMEB  
& THC-HS:HPBCD lyophilized solid dispersions 
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5.3.2. Accelerated stability testing of THC-HS:RAMEB solid dispersions 
 
Figure 5-6: Degradation rate constants of lyophilized complexes of THC-HS/RAMEB 
The degradation rate of the THC-HS in freeze-dried inclusion complexes with RAMEB 
decreased with increasing concentration of RAMEB. In open vials, percent drug remaining at the 
end of 21 days at 25°C, in 1:2 and 1:10 inclusion complexes of THC-HS/RAMEB was 49% and 
66%, respectively. In closed vials, percent drug remaining in the 1:2 and 1:10 inclusion 
complexes of THC-HS/RAMEB was 64% and 83%, respectively at the end of 21 days (fig.5-6; 
fig.5-7). The maximum degradation was observed when the lyophilized inclusion complex of 
THC-HS:RAMEB were stored in open containers (fig.5-7). Higher concentrations of RAMEB 
conferred more stability to the included prodrug.  
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Figure 5-7: Thermal stability of lyophilized complexes of THC-HS/RAMEB 
In open conditions, oxidation as well as hydrolysis of THC-HS due to moisture led to 
higher degradation of the prodrug in the complex. The activation energy was also found to be the 
highest for the THC-HS:RAMEB (1:10) complex as also indicated by a low degradation constant 
(Fig.5-6 & Table 5-1). 
Table. 5-1: Activation energy of lyophilized complexes of THC-HS/RAMEB 
THC-HS :RAMEB 
complex 
Activation 
energy, Ea (J/mol) 
1:2 open 0.868 
1:10 open 2.706 
1:2 closed 3.342 
1:10 closed 3.840 
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Most accelerated testing models are based on the Arrhenius equation: 
 
The above equation describes the relationship between storage temperature and 
degradation rate. Use of the Arrhenius equation permits a projection of stability from the 
degradation rates observed at high temperatures. Activation energy, the independent variable in 
the equation, is equal to the energy barrier that must be exceeded for the degradation reaction to 
occur. When the activation energy is known (or assumed), the degradation rate at low 
temperatures may be projected from those observed at ―stress‖ temperatures.209 
 
Figure 5-8: Arrhenius plot of lyophilized complexes of THC-HS/RAMEB 
The activation energy was highest for THC-HS:RAMEB (1:10 closed) which correlated 
well with the stabilization effect of this formulation on THC-HS. The degradation rate constants 
were also the lowest for THC-HS:RAMEB (1:10 closed) system as evident from Fig.5-6.   
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5.3.3. In Vitro Permeability Studies of lyophilized THC-HS:RAMEB solid 
dispersions 
It is generally recognized that cyclodextrins act as true carriers by keeping the 
hydrophobic drug molecules in solution and deliver them to the surface of the biological 
membrane, where they partition into the membrane. Cyclodextrins can enhance drug permeation 
by increasing drug availability and stability at the surface of the biological barriers. However, 
derivative cyclodextrins, especially methylated cyclodextrins, act as absorption enhancers by 
different pathways. These hydrophobic cyclodextrins act as absorption enhancers, probably, by 
transiently changing membrane permeability, overcoming the aqueous diffusion barrier and 
opening tight junctions. Methyl-b-cyclodextrin, a more hydrophobic cyclodextrin, can permeate 
the buccal mucosa to form inclusion complexes with hydrophobic molecules, namely lipids from 
the cellular membrane, interacting strongly with these lipids; it could modify buccal mucosa 
permeability and could act as penetration enhancer for the buccal route.  
 
Figure 5-9: In vitro permeability profile of THC-HS:RAMEB lyophilized solid dispersions 
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The permeability of THC-HS/RAMEB (1:2) lyophilized complex was increased four-fold 
and that of the 1:10 complex increased two-fold compared to the permeability of the THC-HS 
alone. The lag time associated with the diffusion of THC-HS:RAMEB (1:2) complex was 
negligible, whereas that of 1:10 inclusion complex of THC-HS:RAMEB was approximately 2 hr 
(fig..5-9). This can be attributed to the higher bound concentration of THC-HS with increasing 
concentrations of RAMEB.  
Table. 5-2: Permeability parameters for THC-HS:RAMEB lyophilized solid dispersions 
Diffusion 
parameters 
THC-HS:RAMEB 
(1:2) 
THC-HS:RAMEB 
(1:10) 
Flux (μg/cm2.hr) 9.317 3.5817 
Permeability 
(cm/sec) 
5.084 x 10
-6
 1.955 x 10
-6
 
 
The stability of THC-HS was increased by its complexation with RAMEB. 
Lyophilization was found to be the optimum method of processing THC-HS in a film 
formulation. Freeze-drying also resulted in higher content uniformity than the physically mixed 
prodrug and RAMEB.  Higher concentrations of RAMEB led to lower flux and total amount 
permeated across the buccal mucosa in permeability profiles. Hence an optimum amount of 
RAMEB to be added in films will have to be studied and ascertained to achieve greater stability 
and higher permeation as well across the buccal mucosa. 
5.4. Conclusion 
Out of the two modified cyclodextrins, RAMEB was better able to solubilize the drug 
and enhance the rate of release of THC-HS form solid dispersions as compared to HPBCD. The 
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flux across the buccal mucosa was increased due to the ability of RAMEB to increase the 
concentration of THC-HS at the interface of the buccal membrane. The lyophilized solid 
dispersions of THC-HS-RAMEB were more stable than the drug itself. 
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CHAPTER 6 
Formulation studies of lyophilized solid dispersions of 
 THC-HS-RAMEB 
  
98 
 
6.1. Introduction 
∆9 –Tetrahydrocannabinol (THC), the major pharmacologically active constituent of 
cannabis sativa has been utilized for the treatment of nausea and vomiting in cancer 
chemotherapy.  Due to THC itself being highly lipophilic, water-insoluble and unstable drug, an 
effective dosage form has not developed to date. We have initially reported the formulation 
development of more hydrophilic prodrugs of THC viz; ∆9–Tetrahydrocannabinol hemisuccinate 
(THC-HS) and ∆9–Tetrahydrocannabinol hemiglutarate (THC-HG).30-33,172 Though there have 
been initial reports of formulation development of THC-HS transmucosal films, there is no 
research elucidating the synergistic effect of cyclodextrins and various other formulation 
variables such as anti-oxidants, plasticizers and pH modulating agents on stabilization of THC-
HS in polymeric transmucosal films 
The purpose of the research work was to enhance the stability of lyophilized solid 
dispersions of THC-HS:RAMEB in polymeric transmucosal film system.  
6.2. Methods 
6.2.1. Feasibility testing for preparation of hot-melt cast films of lyophilized THC-
HS-RAMEB solid dispersions 
The lyophilized powders of THC-HS/RAMEB (1:1) were physically mixed with 
polyoxyethylene oxide (PEO; PolyOx
®
) N-80 and exposed to hot-melt processing temperatures 
of 115-125°C, for 5 minutes, to produce a polymeric patch.  
Three types of formulation methods were adopted to assess the stability of THC-HS in 
presence of RAMEB in a hot-melt cast film. 
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F1 – THC-HS:RAMEB (1:1) lyophilized inclusion complex + PEO-N80 
F2 – THC-HS + RAMEB + PEO-N80 (Physical mixture) 
F3 – THC-HS + PEO-N80 (Physical mixture) 
Content uniformity of each type of formulation was determined to establish the most 
feasible method of incorporation of lyophilized THC-HS:RAMEB solid dispersions in hot-melt 
cast patches. 
6.2.2. Effect of RAMEB on stability of THC-HS in hot-melt cast polymeric films 
Hot-melt cast films of THC-HS:RAMEB with PEO-N80 were prepared to determine 
effect of RAMEB on the post-processing content of THC-HS and its storage stability. THC-HS 
was lyophilized with RAMEB (1:1) at -50°C in a lyophilizer. The lyophilized powders of THC-
HS/RAMEB (1:1) were physically mixed with polyoxyethylene oxide (PEO; PolyOx®) N-80 
and exposed to hot-melt processing temperatures of 115-125°C, for 5 minutes, to produce a 
polymeric patch. The patches were stored at four different temperatures viz; -20°C, 4°C, 25°C 
and 40°C. 
6.2.3. Effect of Plasticizers on stability of THC-HS in hot-melt cast polymeric films 
Screening of Plasticizers 
PEO softens at approximately 80
○ 
C; however, the nature of the polymers necessitates the 
use of a processing aid in order to produce a uniform melt. For this purpose, various potential 
plasticizers were tested to evaluate miscibility with PEO. These include vitamin E succinate 
(VES), acetyl tributyl citrate (ATBC), PEG 8000, and triacetin. The suitable 
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plasticizers/additives were further used to facilitate the film formation when incorporated with 
the drug for studying the stability of THC-HS in presence of RAMEB.  
The patches containing the suitable plasticizers selected from the screening studies were 
further stored at four different temperatures, as mentioned above, for stability purposes. The 
types of plasticizers with their concentration used are given below: 
Triacetin (5%w/w), PEG-8000(5%w/w), VES (5%w/w), ATBC (5%w/w), RAMEB (1%w/w) 
6.2.4. Effect of pH modulation on stability of THC-HS in hot-melt cast polymeric 
films 
PEO matrices incorporated with various pH modifiers along with THC-HS:RAMEB (1:1) 
were fabricated utilizing a hot-melt method at 115°C-125°C. The various pH modifiers studied 
included citric acid, fumaric acid, malic acid, and sodium deoxycholate. The processed matrices 
with selected pH modifiers were stored at four different temperatures -20°C, 4°C, 25°C and 40°C 
and analyzed for THC-HS and THC content at various time intervals for up to 3 months utilizing 
the HPLC method. 
6.2.5. Effect of anti-oxidants on stability of THC-HS in hot-melt cast polymeric films 
Earlier preformulation studies have revealed that THC-HS is prone to hydrolysis and 
oxidation. THC-HS is hydrolyzed to its parent compound, THC which might be oxidized to 
cannabinol (CBN) (oxidative degradation product of THC) peak in HPLC analysis. Hence the 
effect of various classes of anti-oxidants on the stability of THC-HS was investigated. 
PEO-N80 polymeric matrices were fabricated incorporated with various anti-oxidants, 
along with the lyophilized solid dispersions of THC-HS:RAMEB (1:1) utilizing  the previously 
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described hot-melt method. The processed matrices were checked for the post-processing content 
of THC-HS and THC utilizing the HPLC method. Two classes of antioxidants were utilized:(i) 
free radical scavengers (BHT, BHA, propyl gallate), (ii) reducing agents or oxygen scavengers 
(ascorbic acid). A combination of these antioxidants was also utilized.  
6.3. Results and Discussion 
For oral transmucosal delivery, a flexible polymeric matrix system that adheres to the 
mucosa for a predetermined period of time is desirable. Hot-melt processing has been 
demonstrated to be a viable method for the preparation of drug –incorporated polymeric films. 
Hot-melt processing requires a pharmaceutical grade polymer that can be processed at relatively 
low temperatures (low melting point or glass transition temperatures) due to thermal sensitivity 
of many drugs. In the present study, lyophilized solid dispersions of THC-HS and RAMEB were 
incorporated in to the hot-melt cast polymeric matrices of Polyox™ N-80 (PEO N-80) intended 
for transmucosal delivery of THC-HS through the buccal mucosa. For fabrication of hot-melt 
polymeric matrices, a processing temperature of at least 20-30°C above the melting point of 
semi-crystalline polymer or glass transition temperature of an amorphous polymer is desirable to 
lower the polymer melt viscosity. The low melting temperature (melting range 57-73°C, based 
on molecular weight) of PEO-N80 facilitates thermal processing to be performed at 110-120°C.  
Hence PEO N-80 was chosen as the base polymer for fabricating drug incorporated matrices. 
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6.3.1. Effect of processing temperature on stability of THC-HS:RAMEB complex 
Formulation type legends 
F1 –THC-HS:RAMEB (1:1) freeze-dried inclusion complex + PEO-N80 
F2 – THC-HS + RAMEB + PEO-N80 (Physical mixture) 
F3 – THC-HS + PEO-N80 (Physical mixture) 
The effect of processing temperature was profound in patches containing only PE0 N-80 
and THC-HS wherein the percent drug remaining was only 13%. The patches containing the 
lyophilized complex of THC-HS/RAMEB showed significantly less degradation at the same 
conditions wherein the percent drug remaining was 49%. THC-HS is degraded to THC and CBN 
as determined by HPLC analysis in all the samples. It is well-known that mono- and polyetheric 
compounds like polyoxyethylene oxides, easily undergo free radical autooxidation during 
storage and upon exposure to heat, light and transition metals to form peroxides which can be a 
source of drug degradation by oxidation.
146
 Also, PEO N-80 consists of ether and hydroxyl 
groups which are capable of potentiating the hydrolysis of THC-HS. RAMEB, however is 
observed to shrink the hydrolysis of THC-HS to THC to a considerable extent as noted form 
Figure 6-1. This is due to the fact that RAMEB protects THC-HS molecule from hydrolysis by 
encapsulating its hydrophobic aromatic ring system in its cavity as well as forming hydrogen 
bonds with the hemisuccinate ester linkage.  
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Figure 6-1: Effect of processing method on stability of THC-HS:RAMEB 
6.3.2. Content uniformity of hot-melt cast films containing THC-HS:RAMEB 
complex  
The content uniformity of freeze-dried lyophilized powders of THC-HS:RAMEB 
complex as well as physical mixtures of THC-HS and RAMEB was determined to optimize the 
method of incorporation of RAMEB in the films. 
 
Figure 6-2: Effect of processing method on content uniformity of  
THC-HS:RAMEB complexes 
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 Lyophilized powders of THC-HS and RAMEB exhibited a satisfactory content 
uniformity and the handling of powders was easier than the plain physical mixtures of THC-
HS:RAMEB (fig 6-2). Lyophilization led to more intimate mixing and ease in complex 
formation of THC-HS with RAMEB.  
6.3.3. Effect of RAMEB on stability of THC-HS in hot-melt cast polymeric matrix 
 
Figure 6-3: Stability of THC-HS:RAMEB (1:1) in PEO-N80 Matrices 
THC-HS:RAMEB lyophilized solid dispersions incorporated in a polymeric hot-melt cast 
patch were stable at -20°C and 4°C up to 2months but showed significant degradation at 25°C 
and 40°C (fig 6-3). 
6.3.4. Effect of Plasticizers / Processing aids of THC-HS in hot-melt cast polymeric 
matrix 
Plasticizers are typically low molecular weight compounds capable of softening polymers 
to make them more flexible. The use of polymeric carriers in hot-melt extrusion often requires 
the incorporation of a plasticizer into the formulation to improve the processing conditions 
105 
 
during the manufacturing of the extruded dosage form or to improve the physical and mechanical 
properties of the final product. 
Plasticization of the polymer is generally attributed to the intermolecular secondary 
valence forces between the plasticizer and the polymer. Plasticizers are able to decrease the glass 
transition temperature and the melt viscosity of a polymer by increasing the free volume between 
polymer chains. In so doing, the ease of movement of polymer chains
150
 with respect to each 
other is dramatically reduced. Plasticizers were also found to facilitate the fusion process of 
semi-crystalline polymers. With the addition of a plasticizer, a hot-melt extrusion process can be 
conducted at lower temperatures and with less torque. Both the active ingredient and the polymer 
will be more stable during the extrusion process due to these improved processing conditions. 
Various plasticizers such as triacetin, PEG 8000, vitamin E succinate (VES), acetyl tributyl 
citrate were incorporated in to PEO N80-THC-HS-RAMEB matrices.  
Overall, incorporation of plasticizers lowered the degradation rate of THC-HS in THC-
HS:RAMEB solid dispersions in hot-melt cast films as compared to PEO-N80 matrices only (fig 
6-4). Also, the films processed in presence of plasticizers were easy to fabricate and showed 
excellent content uniformity.  The plasticizers acted synergistically along with RAMEB to 
reduce the degradation of THC-HS in the hot-melt cast films.  
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Figure 6-4: Effect of plasticizers on polymeric matrices of THC-HS:RAMEB 
VES was found to be the best plasticizer among all the plasticizers tested followed by 
ATBC as regards to the post-processing content of THC-HS. The degradation of drug in the 
various PEO matrices was found to be in the order of PE) N80 only > PEO N80-RAMEB > PEO 
N80-RAMEB- PEG 8000 > PEO N80-RAMEB-triacetin > PEO N80-RAMEB- ATBC > PEO 
N80-RAMEB- VES. It is observed that THC-HS degraded to a higher extent in the presence of 
hydrophilic plasticizers like PEG 8000, triacetin as compared to relatively hydrophobic 
plasticizers such as VES and ATBC. These findings are consistent with Munjal et al and 
Thumma et a
30,172,210
l who also reported significant degradation of THC prodrugs in presence of 
hydrophilic excipients.  
The stability testing provides evidence on how the quality of an active varies with time 
under the influence of a variety of environmental factors such as temperature and humidity. The 
stability testing results indicate that though the immediate post-processing content  of THC-HS 
was improved with the addition of plasticizers in hot-melt transmucosal films, the content of 
THC-HS at the end of three months dropped significantly at all temperature and humidity 
conditions (fig 6-5). These results suggest that further optimization of the formula is required to 
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improve the post-processing content of THC-HS in transmucosal films.  In stability testing, 
overall, plasticizers were found to work synergistically with RAMEB to augment the 
stabilization effect of RAMEB in lyophilized solid dispersions of THC-HS. 
 
 
 
Figure 6-5: Stability testing of plasticizers in polymeric matrices of THC- HS:RAMEB 
6.3.5. Effect of pH modulation of THC-HS in hot-melt cast polymeric matrix 
It is well-known that the degradation arte of drugs is affected by the microenvironmental 
pH to which they are exposed in the solid dosage forms. Studies on enhancing the stability of 
drugs with the use of pH modulators into the formulations have been reported previously.
211,212
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THC-HS has been reported to exhibit alkali-catalyzed hydrolysis and it might be beneficial to 
incorporate acidic pH modulating agents to improve the hydrolytic stability of THC-HS in hot-
melt transmucosal films. Various acid pH modulating agents such as citric acid, malic acid, 
fumaric acid were incorporated into PEO N80-THC-HS-RAMEB matrices. It was found that 
citric acid had the most profound positive effect on stability of THC-HS in transmucosal films.   
Table.6-1: pH modulation achieved by different pH modulators 
Patch formulation 
%w/
w 
pH 
% THC-HS 
remaining 
Citric acid 2% 4 82 ±0.97 
Malic acid 2% 4.78 75 ± 1.2 
Fumaric acid 2% 5.32 69 ± 0.73 
Sodium Deoxycholate 
(NaDC) 
2% 7.6 57 ± 1.48 
Citric acid + 2% NaDC 2% 4.56 72 ± 1.37 
 
THC-HS:RAMEB polymeric matrices of PEO-N80 containing citric acid reduced the 
degradation of THC-HS considerably with 82% post-processing content as against 46 % in 
patches containing no acid modulating agents (fig 6-6).  The other acid modifiers did not seem to 
offer any advantage over citric acid. The results of stability testing also indicated a significant 
improvement in the content of THC-HS in transmucosal films.  
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Figure 6-6: Stability testing of citric acid as pH modifier in polymeric matrices of THC-
HS:RAMEB 
 
Figure 6-7: Stability testing of citric acid + Sodium deoxycholate as pH modifier in 
polymeric matrices of THC-HS:RAMEB 
The effective pH range for stable hot-melt cast PEO N80 matrices of THC-HS :RAMEB 
solid dispersions were found to be in the range of 4.0-4.5.  
6.3.6. Effect of anti-oxidants of THC-HS in hot-melt cast polymeric matrix 
Drugs may undergo oxidation due to reactive impurities that are added during polymer 
manufacturing or generated upon exposure of the excipient or formulation to light, heat or 
110 
 
metals.
146
 THC formed after the hydrolysis of THC-HS is known to degrade by oxidation in 
addition to hydrolysis of the ester bond in prodrug.  Polyethylene oxide has been reported to be 
protected from free radical and oxidative degradation by the incorporation of an antioxidant. 
Various classes of antioxidants were incorporated into the PEO N80-THC-HS-RAMEB matrices 
and stored at different temperature and humidity conditions to assess their role in preventing the 
prodrug degradation.  The concentrations of antioxidants used in the study are given in table 6-2. 
Table.6-2: Screening of anti-oxidants 
Antioxidant % w/w 
PEO-N80 - 
RAMEB 1 
VES 5 
Citric acid 2 
BHT 0.02 
BHA 0.2 
Propyl gallate 0.5 
Ascorbic acid 1 
BHT + Propyl gallate 0.02 + 0.5 
BHT + Ascorbic acid 0.02 + 0.5 
 
 
Figure 6-8: Effect of antioxidants on stability of THC-HS 
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 Almost all of the antioxidants incorporated into the PEO-N80-THC-HS:RAMEB 
matrices reduced the degradation of THC-HS as compared to PEO-N80-THC-HS:RAMEB only 
matrices. However, degradation of the drug continued even in the presence of anti-oxidants.  
BHT and the combination of BHT + Propyl gallate showed significant advantage (p < 
0.05) with 76.35% and 71% post-processing content over the other anti-oxidants (Fig.6-8). 
6.4. Conclusion 
The results of the present study clearly underlines the importance of formulation variable 
sin producing stable polymeric transmucosal films of THC-HS. Further optimization of the 
formula needs to be done to study the critical formulation variables for stability of THC-HS in 
hot-melt transmucosal films as well as the interactions, if any between the individual excipients. 
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CHAPTER 7 
Application of factorial design to identify critical formulation 
variables in the design of hot-melt transmucosal films of THC-HS 
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7.1. Introduction 
Δ9-Tetrahydrocannabinol (THC), the major pharmacologically active constituent 
of Cannabis sativa exhibits therapeutic potential in the treatment of nausea and vomiting during 
cancer chemotherapy. The only commercially available USFDA approved dosage form for 
treatment in chemotherapy-related nausea and vomiting is the soft gelatin capsule for oral 
administration, marketed in the USA as Marinol
® 
and two of its generic versions. In this 
formulation, however, the drug has limited stability and therefore has to be stored at low 
temperatures (4 °C). Moreover, the oral bioavailability of the drug is low ( 6%) and 
inconsistent, which is mainly due to its high first-pass metabolism and poor solubility.
163
 In 
addition to the pharmacokinetic limitations, the physicochemical properties of THC present a 
major challenge in the development of a suitable dosage form. THC is a poorly water-soluble, 
amorphous substance which is sticky, resin-like and highly viscous, making it difficult to handle 
and process. Furthermore, the instability of THC, especially in acidic solutions, and when 
exposed to heat, air and light has been reported by various researchers. To overcome the 
challenges of THC molecules in terms of its unfavorable physicochemical properties as well as 
high first pass metabolism, we have designed novel hydrophilic prodrugs of THC to be 
administered by buccal route in the form of transmucosal films. To enhance the solubility and 
stability of a novel first-generation THC prodrug, Δ9-Tetrahydrocannabinol hemisuccinate 
(THC-HS), various formulation additives such as random methylated beta cyclodextrin 
(RAMEB as solubilizer), Vitamin E succinate (VES as a plasticizer) and citric acid (CA as a pH 
modulating agent) were employed to produce a stable hot-melt cast transmucosal films for 
buccal application.  
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During formulation development of a stable product, design of experiments methodology 
allows the systematic evaluation of the effect of formulation variables, with a minimum number 
of experiments, in order to identify the critical parameters.
213
  
Quality by design (QbD) is one such FDA initiative to pharmaceutical development 
(FDA guidance of industry, 2006). The objective of QbD approach is to design a process in such 
a way that manufactures pharmaceuticals that consistently meet critical quality attributes. A 
process and formulation can be better understood if the design is based on multivariate analysis 
which identifies critical formulation factors and as well as root causes of variability in the 
formulation. In the current study, we studied the effects of the formulation additives on the post-
processing content as well as the release rate of THC-HS from the transmucosal films using 
statistical 2
3
 full factorial design.  
7.2. Materials 
The following chemicals were used as received: randomly methylated beta-CD 
(RAMEB) were purchased from Sigma Aldrich with a degree of substitution of 1.7 and 0.6, 
respectively. PEO [PolyOx
®
 WSR N-80 (PEO N-80), MW 200,000 Da] were kindly donated by 
Dow Chemical Company (Midland, MI). Vitamin E succinate (VES), citric acid anhydrous, 
malic acid, fumaric acid, sodium lauryl sulfate (SLS) were purchased from Spectrum Chemical, 
Inc. (Gardena, CA). HPLC-grade water was freshly prepared in the laboratory (by Nanopure 
systems, Barnstead, Dubuque, IA). HPLC-grade acetonitrile and methanol and were obtained 
from Fisher Scientific, Fair Lawn, NJ; THC-HS (in hexane) and THC (in absolute ethanol) were 
provided by ElSohly Laboratories Inc, Oxford, MS. 
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7.3. Methods 
7.3.1. Experimental Design 
A 2
3
 full factorial design was created to determine and optimize the effect of the three 
formulation factors using two responses. Three continuous factors, percent content of RAMEB, 
VES and CA were tested at two levels designated as -1 and +1, respectively with 0 as the 
centerpoint. The dependent variables analyzed were as follows: post-processing content of THC-
HS and dissolution profile of THC-HS at 60 minutes. Table.1 lists the factor levels for 11 film 
formulations as per the design. 
7.3.2. Preparation of hot-melt cast polymeric films of THC-HS  
Hot-melt cast films of lyophilized solid dispersions of THC-HS:RAMEB with PEO-N80 
were prepared to determine the effect of RAMEB, VES and CA on the post-processing content 
and the release rate  of THC-HS from its polymeric matrices.  THC-HS was lyophilized with 
RAMEB at -50°C in a lyophilizer. The lyophilized powders of THC-HS/RAMEB were 
physically mixed with polyoxyethylene oxide (PEO; PolyOx
®
) N-80 and exposed to hot-melt 
processing temperatures of 110°C, for 5 minutes, to produce a polymeric film. Briefly, a die 
containing a 13-mm diameter opening was placed on top of a brass sheet and heated at 110 °C. 
Approximately 200 mg of the physical mixture of lyophilized solid dispersions of THC-HS and 
RAMEB, PEO N80 and other excipients was positioned in the orifice of the die, and compressed 
using a punch. This compressed mixture was heated for 5 min to form a melt, followed by 
cooling under room conditions to form a thin polymeric film. Film thickness ranged from 1.1 to 
1.3 mm. The diameter of the films produced was approximately 12.9 ± 0.2 mm. 
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7.3.3. In vitro characterization 
Sample preparation for post-processing content of THC-HS from transmucosal films 
A weighed portion of the THC-HS or drug-incorporated polymeric matrix was dissolved 
in a known volume of methanol by sonicating it for 10 min. The resulting solution was 
centrifuged at 16000 rpm for 10 minutes, supernatant transferred into vials and 20 μL was 
injected into the HPLC column for drug analysis. 
7.3.4. In vitro release studies 
The effect of all the formulation additives on the release of THC-HS from 
the PEO matrices was investigated. All the selected excipients were incorporated into 
the PEO matrices along with the lyophilized solid dispersions of THC-HS and RAMEB utilizing 
the hot-melt method at 110º C.  In vitro release studies (n = 3) were performed on these matrices 
utilizing a Hanson SR8-Plus dissolution test system according to USP 31 apparatus 5, paddle 
over disk method. The polymeric matrix was sandwiched between the watch glass and a mesh so 
that the release was unidirectional. Five hundred milliliters of pH 6.8 phosphate buffer 
containing 0.5% w/v SLS at 37 °C was used as the dissolution medium and the paddle rotation 
speed was 50 rpm. Samples were collected at pre-determined time intervals and replaced with an 
equal volume of the fresh dissolution medium. The samples were then centrifuged at 16000rm 
for 15 minutes and supernatant analyzed by a validated HPLC method. The cumulative percent 
of drug dissolved at the end of 60 minutes (T60 %) was used as the endpoint for calculations in 
the factorial design. 
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7.3.5. Chromatographic analysis 
The chromatographic system consisted of a Waters 600 pump and a dual wavelength 
Waters 2487 UV detector (Waters Corp., Milford, MA). A Symmetry 5μ C-18, 
250 mm × 4.60 mm column (Waters Inc.), was used for the detection of the drug. The mobile 
phase consisted of 80%acetonitrile and 20% pH 3 monobasic potassium phosphate buffer 
containing 0.1% triethyl amine, pH adjusted to 3 with phosphoric acid. The flow rate was 
maintained at 1.2 mL/min, with THC-HS and THC eluting within 15 min. The injection volume 
was 20 μL, and the column effluent was monitored by UV absorption at 215 nm. The 
temperature of the column was maintained at 25 °C. 
7.3.6. Statistical Analysis 
StatGraphics™ Centurion (StatPoint, Inc., Version XV) was used to generate the 23 full 
factorial study designs and to perform the statistical analysis. Data obtained from the 
experimental formulation testing was analyzed by analysis of variance (ANOVA). The 
polynomial equation of the model is as follows: 
Y = b0 + b1 A + b2 B + b3 C + b12 AB + b13 AC + b23 BC 
where Y is the dependent variable; b0 is the intercept; b1 to b23 are the regression coefficients; and 
A, B and C are the independent variables selected for the experiments. 
7.4. Results and Discussion 
Eleven formulations were prepared (Table 1 & 2), as designed by the full factorial 
experimental design for the three factors studied. Table 3 gives the measured post-processing 
content and the release of THC-HS from the transmucosal films at the end of 60 minutes. The 
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design was evaluated by multiple linear regression analysis, and the mathematical relationships 
in the form of regression equations for the measured dependent variables along with the other 
statistical parameters are given in Table 4.  
The results clearly indicate that the content as well as the release of THC-HS from the 
films is strongly affected by the variables selected for the study. This is also reflected by the 
wide range of values for coefficients of the terms mentioned in the equations in Table 4. The 
main effects of A, B and C represent the average result of changing one variable at a time from 
its low level to its high level. The interaction terms (AB, AC, BC) show how the dependent 
variables change when two independent variables are simultaneously changed. The negative 
coefficients in the equation represents an inverse relationship between a response and factor 
where as a positive value represents a favorable response.   
Table 7-1. Factor Levels for the 2
3
 Factorial Design 
Coded levels of 
Independent 
variables 
-1 1 0 (centerpoint) 
Factor A : CA (%) 0.25 2 1.125 
Factor B: VES 
(%) 
0.5 5 2.75 
Fcator C: RAMEB 
(%) 
4 8 6 
Dependent 
variables 
Post processing content of THC-
HS (Y1) 
% Release of THC-HS at 60 
minutes (T60 %) (Y2) 
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Table 7-2: 2
3
 Factorial Design for independent variables 
Independent 
Variables  
F1  F2  F3  F4  F5  F6  F7  F8  F9  F10  F11  
VES (%)  0.5  
(-1)  
5 
(+1)  
0.5  
(-1)  
5 
(+1)  
0.5 
(-1)  
5 
(+1)  
0.5 
(+1)  
5 
(+1)  
2.75 
(0)  
2.75 
(0)  
2.75 
(0)  
CA (%)  0.25  
(-1)  
0.25  
(-1)  
2 
(+1)  
2 
(+1)  
0.25  
(-1)  
0.25 
(-1)  
2 
(+1)  
2 
(+1)  
1.125 
(0)  
1.125 
(0)  
1.125 
(0)  
RAMEB 
(%)  
4  
(-1)  
4  
(-1)  
4  
(-1)  
4  
(-1)  
8 
(+1)  
8 
(+1)  
8 
(+1)  
8 
(+1)  
6  
(0)  
6  
(0)  
6  
(0)  
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Table 7-3: Measured Responses (dependent variables) for the film formulations 
FORMULATION THC-HS CONTENT (%) 
(n=3) (Y1) 
THC-HS RELEASE (T60 
%)* 
(n=3) (Y2) 
F1 60.53±1.28 18.34±2.3 
F2 69.58±0.83 16.31±1.97 
F3 84.55±0.47 51.76±2.8 
F4 86.43±0.32 43.56±3.8 
F5 77.56±1.1 38.34±1.45 
F6 69.38±0.92 45.63±3.7 
F7 95.06±0.61 72.23±3.6 
F8 98.57±0.75 61.05±4.2 
F9 83.24±1.34 50.32±3.9 
F10 85.45±0.94 56.71±2.2 
F11 84.67±1.02 58.95 ±3.1 
*T60 %, % Drug release at the end of 60 minutes 
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Table  7-4: Statistical analysis of dependent variables Y1 and Y2 along with the regression equations 
  
% Content – 
THCHS (Y1) 
 
% Release-THCHS 
(Y2) 
 Coefficient F ratio p- value Coefficient F ratio p- value 
Constant(b0) 48.0604   -9.0049   
CA % (A) 9.24764 44.56 0.0026 24.882 16.38 0.0155 
VES % (B) 2.602 0.22 0.6618 -0.08111 0.27 0.6308 
RAMEB % 
(C) 
3.195 9.08 0.0394 5.883 10.32 0.0325 
R
2
  93.2855  87.5061 
 
7.4.1. Influence of formulation variables on post-processing content of THC-HS in 
transmucosal films (Y1) 
The post-processing content of THC-HS in transmucosal films is dependent on several 
process-parameters as well as formulation excipients present in the films. The films were 
produced using hot-melt cast method wherein THC-HS is exposed to higher temperature (110°C) 
albeit, for few minutes during which the polymer PEO N80 melts to form a uniform film. For the 
purposes of this experimental design, the time and the temperature of the melt-casting process 
were kept constant at 110°C for 5 minutes so as to avoid their influence on the content of THC-
HS in the processed films. THC-HS, as discussed earlier 
197
 is an ester prodrug with a high 
hydrolytic potential. It is also unstable to heat and oxidation. Hence to improve the stability of 
THC-HS in hot-melt cast transmucosal films, a proper choice of excipients including plasticizers, 
pH modulating agents and solubilizers is warranted. Here we have chosen three formulation 
additives viz., citric acid (pH modulating agent), Vitamin E succinate (VES, plasticizer) and a 
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modified cyclodextrin, random methylated beta cyclodextrin (RAMEB, solubilizer) to produce 
an improved formulation of THC-HS. The rapid hydrolysis of ester prodrug, THC-HS to its 
highly lipophilic and water-insoluble parent drug THC in neutral as well as alkaline pHs results 
in lower post-processing content of THC-HS in transmucosal films.  
The degradation rate and profile of THC-HS are affected by the microenvironmental pH 
of the polymeric transmucosal films.  For overcoming pH-dependent behavior of drugs, pH-
modifying excipients (which alter the microenvironment pH inside the formulation) are most 
commonly used.  
This strategy provides an opportunity to improve the stability of a formulation by 
providing the optimal ‗pH‘ for the drug to maximize its stability. The ‗pH‘ of a formulation is 
determined by the nature and possibly the concentration of the active ingredient and the various 
excipients. Acidic or basic ingredients (pH modifiers) can be intentionally added to a formulation 
for the sole purpose of modifying the ‗pH.‘ Here, we have applied the concept of modifying the 
microenvironmental pH of THC-HS for enhancing the stability of THC-HS in transmucosal 
films. 
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Figure 7-1: Effect of acidic pH modulating agents on post-processing content of THC-HS 
It has been shown earlier that THC-HS is stable at acidic pHs between 3.5 -5.5. As a part 
of preliminary investigation, we studied the effect of different acidic pH modifiers such as citric 
acid, fumaric acid and malic acid on the post-processing content of THC-HS (Fig.1). Out of all 
the three pH modifiers, citric acid showed the highest post-processing content of THC-HS. 
Despite having similar pKa values (˷3), citric acid showed significant enhancement in stability of 
THC-HS.  Due to the higher solubility of citric acid, its saturated solution pH was found to be 4 
compared to 5 and 5.32 for malic and fumaric acid respectively.
214
 Citric acid was therefore 
chosen as a pH modulating agent for the optimization process. The appropriate concentration of 
the pH modifier in a solid formulation required to achieve desired ‗pH‘ control is not always a 
straightforward decision. A minimum concentration of the pH modifier is probably needed to 
achieve needed ‗pH‘ control. This concentration is likely dependent on particle size of the 
formulation ingredients and the pH modifiers and on the manufacturing process. Increasing the 
pH modifier content above this minimum concentration is not expected to achieve a more 
effective ‗pH‘ control and hence provides no further stability improvement. 
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Figure 7-2: Standardized pareto chart and Main effects  
for post-processing content of THC-HS (Y1) 
In this case, we have chosen two levels of citric acid, 0.5% and 2% yielding pHs 6.0 and 
4.0 respectively. The standardized pareto and the Main Effects plot in Figure.1 illustrate citric 
acid had a positive effect on content of THC-HS from the film.  Citric acid at the highest level in 
this design reduced the ester hydrolysis of THC-HS to THC thereby increasing its post-
processing content.  As expected, increasing concentration of citric acid in the formulation 
increased the post-processing content of THC-HS by the virtue of reducing the 
microenvironmental pH in the transmucosal film. Increasing the pH of the film formulation 
beyond pH 4.0 would have caused irritation to the buccal mucosa. Therefore within the range 
chosen, the confidence that the model can predict the observed value better than the mean was 
83.21% and good correlation was obtained between observed and predicted value as indicated by 
R
2
 value of 0.932 (Table 4). From the F ratios given for Y1, it can be concluded that citric acid 
had the most significant effect (P < 0.05) on the post-processing content of THC-HS from the 
film. 
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Another factor that significantly impacted the post-processing content of THC-HS was 
the concentration of RAMEB. Cyclodextrins are known to solubilize lipophilic drugs through 
inclusion phenomena. The standardized pareto chart and the Main Effects plot (Fig.7-2) clearly 
illustrate the effect of RAMEB on post-processing content. The content of THC–HS in the films 
increased with the increasing percentage of RAMEB in films. The coefficient of RAMEB also 
suggests that it has a positive effect on the content of THC-HS.   In a previous communication
197
, 
we had demonstrated an increase in solubility of THC-HS by its inclusion into the hydrophobic 
cavity of RAMEB thereby rendering it hydrophilic. We also demonstrated that the ester side 
chain of the prodrug was involved in the hydrogen bonding interactions with the hydroxyl groups 
on the rim of RAMEB molecule. It is thought that RAMEB increases the stability of THC-HS by 
encapsulating the molecule in its hydrophobic cavity thus reducing its exposure to heat and 
oxidation. More specifically, RAMEB significantly (P < 0.05) reduces the hydrolysis of THC-
HS to THC by protecting its ester linkage through hydrogen bonding interactions. From the F 
ratios in ANOVA table, RAMEB acts synergistically along with citric acid and significantly (P < 
0.05) increases the post-processing content of THC-HS in the transmucosal films.  
From the standardized pareto chart and the Main Effects plot (Fig.7-2), VES did not show 
a statistically significant effect on the content of THC-HS. The post-processing content of THC-
HS did not increase on increasing the concentration of VES in the films. This may be due to the 
fact it is not essential for actual stability of THC-HS. The definite role of VES in hot-melt cast 
films is that of plasticizing the polymer PEO N80 by reducing its melt viscosity and ultimately 
lowering the temperature of casting films.  The lower concentrations of VES might just be 
sufficient to improve the melt viscosity of the polymer. This was also corroborated by the results 
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obtained by Thumma et al in which the stabilization effect of VES was sealed off at 20%w/w in 
the transmucosal films.
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The F ratio from ANOVA indicated that VES did not have any statistically significant 
effect (P > 0.05) of post-processing content of THC-HS. 
7.4.2. Influence of investigated formulation variables on dissolution profile of THC-
HS in the transmucosal films (Y2) 
Table. 3 illustrates the dissolution profiles at the end of 60 minutes for the eleven film 
formulation prepared for the study. The standardized pareto chart and Main Effects plot for T60 
% (% drug released at the end of 60 minutes) shown in Fig. 7-3 demonstrate that the 
concentration of pH modulating agent,  citric acid and synthetic modified cyclodextrin, RAMEB 
had the greatest effect on the dissolution profile and that the effect was statistically significant. 
All formulations with higher levels of citric acid (F7, F8, F3, F4) exhibited higher % release of 
THC-HS from the polymeric transmucosal films. From the regression equation for %THC-HS 
release, it is clear that the coefficient for the independent variable, citric acid is the highest 
among all the coefficients of other independent variables. From the F ratio of ANOVA table, 
citric acid is the most significant factor affecting the release of THC-HS from the transmucosal 
films. This can be explained on the basis of stabilization mechanism of THC-HS. By virtue of 
being able to modulate the microenvironment pH in the transmucosal films, citric acid reduces 
the hydrolysis rate of hydrophilic prodrug, THC-HS to more hydrophobic water-insoluble parent 
molecule, THC. 
This phenomenon increases the fraction of hydrophilic prodrug THC-HS in the polymeric 
PEO N80 matrix thereby enhancing its the dissolution rate from the polymeric film.  
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Figure 7-3: Standardized pareto chart and Main effects for  
post-processing content of THC-HS (Y2) 
The second most significant factor affecting the release of THC-HS from the 
transmucosal films is RAMEB. RAMEB significantly enhanced the dissolution rate of THC-HS 
from the films as indicated by F ratio (P < 0.05) from the ANOVA table. This phenomenon can 
be explained by the unique capability of RAMEB to solubilize lipophilic water-insoluble drugs 
through inclusion phenomenon. RAMEB encapsulated the lipophilic portion of THC-HS into its 
hydrophobic cavity whereas the hemisuccinate ester side chain was protected by hydrogen 
bonding interactions occurring with hydroxyl groups on the rim of RAMEB molecule. The 
solubilization of THC-HS by RAMEB increases the hydrophilic fraction of THC-HS in the 
polymeric matrix thus enhancing the diffusion of the drug once the film is wetted by the 
dissolution medium.   
As expected, VES did have a negative, though not significant influence on the release of 
THC-HS from the polymeric PEO N80 matrices. At the microenvironmental pH of 4 -5 created 
by addition of citric acid to the formula, VES was largely present in unionized form, its 
approximate pka being 4.13.
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 The unionized lipophilic form of VES hindered the dissolution of 
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THC-HS from the hydrophilic polymeric matrix transmucosal films. The increasing 
concentrations of VES aggravated the problem further giving rise to the slower release profiles 
observed in formulations F2 and F4. The negative effect on dissolution profile of THC-HS by 
VES was not statistically significant as indicated by F ratio in ANOVA (P > 0.05).  
The interactions observed in Fig7-.4. in this case between citric acid as well as VES (AB) 
though not significant can be explained in terms of presence of insoluble unionized form of VES 
hindering resistance to the dissolution of more hydrophilic THC-HS.  
 
Figure 7-4: Interactions plot for % release of THC-HS at 60 minutes 
The value of the correlation coefficient (R
2
) of the regression equation for THC-HS 
release was found to be 0.88, indicating a moderate fit.  
The replicated centerpoints in the factorial design provided additional degrees of freedom 
and made it possible to assess the pure error of the experiments and enabled the model‘s lack of 
fit to be checked. In this study, the model was checked for lack of fit for both the responses, post-
processing content and % release of THC-HS at 60 minutes. For lack of fit P values, we obtained 
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0.0969 and 0.126 for post-processing content and % release of THC-HS at 60 minutes 
respectively. Hence the current model provided a satisfactory fit to the data (P > 0.05) and had 
no lack of fit.  
7.4.3. Checkpoint Analysis 
Three checkpoint batches were prepared and evaluated for post-processing content and 
release of THC-HS from polymeric matrices at the end of 60 minutes. When measured values 
were compared with predicted values using Student‘s t test (Table.5), the differences were found 
to be insignificant (P >0.05). Thus we can conclude that the obtained mathematical equation is 
valid for predicting the THC-HS content and dissolution from the transmucosal films. 
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Table 7-5: Checkpoint batches with their Predicted and Measured values of post-processing content and 
% release of THC-HS at the end of 60 minutes.  
Batch 
Code 
A 
(Citric 
acid) 
B 
(VES) 
C 
(RAMEB) 
THC-HS content (%) THC-HS 
release at 
60 
minutes 
(T60 %) 
 
    Measured Predicted Measured Predicted 
E1 1 -1 1 96.2 98.56 75 73.95 
E2 1 1 -1 87.88 89.93 47.98 45.27 
E3 1 1 1 98.57 97.38 63.05 65.83 
7.5. Conclusion 
The polymeric transmucosal films of THC-HS with improved process stability and 
release characteristics were successfully prepared with the help of the statistical design.  
Statistical analyses indicate that pH modulation by citric acid and solubilization with the 
aid of RAMEB are important factors controlling the stability and release rate of THC-HS from 
polymeric transmucosal films. Hydrophobic plasticizers such as VES hinder the release of THC-
HS from the films. The higher concentrations of citric acid and RAMEB resulted in higher post-
processing content and release of THC-HS from the films. All the independent variables studied 
had significant involvement on the outcome of the dependent variables. The design of 
experiments methodology assisted in identifying the critical formulation variables in the 
formulation development of transmucosal films of THC-HS. The encouraging results from the 
study prompted us to believe that the stable and highly bioavailable transmucosal films of THC 
can be produced by taking advantage of prodrug solubilization and stabilization strategy. The 
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reduced number of runs and consolidated information obtained in this study helped in 
minimizing the amount of drug used in the formulation development of novel hydrophilic 
prodrug of THC viz., THC-HS.  
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CHAPTER 8 
Preformulation studies of THC-Aminophenylbutyrate  
(THC-APB) 
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8.1. Preformulation studies of THC-Aminophenylbutyrate (THC-APB) 
THC-Aminophenylbutyrate (THC-APB) was synthesized with an objective of obtaining 
better stability characteristics than the existing ester prodrugs like THC-HS. Preformulation 
studies of THC-APB were carried out and include intrinsic solubility, pH solubility, pH stability 
studies, log p and pKa determination.  
8.2. Methods 
Intrinsic solubility was determined in water by equilibration for 3 days. pH solubility 
studies involved a 3-day incubation study of THC-Aminophenyl butyrate (THC-APB)  in buffer 
solutions ranging in pH from 3-9.  
Stability of THC-APB in pH 3, 5, 7.4 and 9 -phosphate buffer at 25°C was determined. A 
prodrug stock solution (100 μL) in ethanol was subsequently added to the 1 ml of buffer 
solutions to yield a concentration of 10µg/ml. The vials were placed in a constant shaker bath set 
at 25°C and 60 rpm. Samples (100 μL) were collected at appropriate time intervals for up to 72 
hours and stored at –80°C until further analysis. Linear regression of the log concentration versus 
time profiles yielded the pseudo first order rate constants of degradation.  
Feasibility testing of THC-APB for transmucosal delivery was carried out by formulating 
of hot-melt cast patches. Briefly hot-melt cast patches were prepared using a die and punch. The 
mixture of hot-melt polymer, excipient and prodrug was heated at 120°C for 5mins and then 
punched to form a flat circular thin patch. The effect of citric acid on stability of THC-APB hot-
melt cast patches was also studied to determine the effect of pH on solid state stability of prodrug 
in the patch matrix. 
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8.3. Results and Discussion 
8.3.1. Preformulation studies of THC-APB 
Table 8-1: Physicochemical properties of THC-APB 
Physicochemical properties 
Solubility 15µM 
pKa 5,66, 7.47 
clogP 7.954 
tPSA 61.55 
 
THC-APB was found to exhibit higher aqueous solubility as compared to the parent drug 
THC (15 µM vs. 2.2 µM). In this prodrug, multiple species with varying solubility are present. 
Solubility of the prodrug was found to be highest in the acidic pH. Presence of basic groups in 
the structure resulted in a higher solubility in acidic pH. This also explains a reduced solubility in 
higher pH.  
 
Figure 8-1: pH solubility profile of THC-APB 
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Figure 8-2: pH degradation profile of THC-APB 
The hydrolysis followed apparent first order kinetics, and the rate constants (K) were 
obtained as slopes from the semi-logarithmic plots of the unchanged prodrug concentration 
versus time. The degradation rate constant was found to be the lowest at pH 5 which indicates 
that the drug is most stable at pH 5 (of those pH tested). Also, the drug undergoes alkaline 
hydrolysis which was clearly evident from high k values at pH 9. 
Table 8-2: Degradation rate constants for THC-APB 
pH k (hr
-1
) 
t ½ 
(days) 
3 0.0061 4.73 
5 0.0018 16.04 
7.4 0.0088 3.28 
9 0.014 2.06 
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Figure 8-3: Effect of citric acid on stability of THC-APB 
Also the content of THC-APB in hot-melt patches containing citric acid is less (83%) as 
compared to that of the patches devoid of citric acid (89%). This can be attributed to the variable 
solubility of the ionized and unionized prodrug at acidic pH. THC-APB was found to be 
reasonably stable at higher casting temperatures than the parent drug, THC.  
8.4. Conclusion 
Although THC-APB exhibited lower solubility than THC-HS, it was found to have better 
characteristics as regards to its hydrolytic stability in comparison to THC-HS. When exposed to 
hot-melt cast temperatures, THC-APB showed significantly higher immediate post-processing 
content than THC-HS. It is definitely worthwhile exploring the feasibility of developing THC-
APB transmucosal films. 
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